Podcasts about Accreditation

"You also want to deal with patient preferences. We do want to get their disease under control. We want to make them live a long, good quality of life. But do they want to come to the clinic once a week? Is it a far distance? Is geography a problem? Do they prefer not taking oral chemotherapies at home? We have to think about what the patient's preferences are to some degree and kind of incorporate that in our decision-making plan for treatments for relapsed and refractory myeloma," Ann McNeill, RN, MSN, APN, nurse practitioner at the John Theurer Cancer Center at Jersey Shore University Medical Center in Neptune, NJ, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about multiple myeloma treatment considerations. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 6, 2027. Ann McNeill has disclosed a speakers bureau relationship with Pfizer. This financial relationship has been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the treatment of multiple myeloma. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 398: An Overview of Multiple Myeloma for Oncology Nurses Episode 395: Pharmacology 101: Monoclonal Antibodies Episode 372: Pharmacology 101: Proteasome Inhibitors ONS Voice articles: Effective Care Transitions Are Essential for New Multiple Myeloma Treatments New Multiple Myeloma Treatments Present New Challenges in Side Effect Management Reduce Racial Barriers and Care Inequities for Black and African American Patients With Multiple Myeloma ONS Voice FDA approval alerts ONS Voice oncology drug reference sheets: Belantamab mafodotin-blmf Daratumumab Motixafortide Selinexor Clinical Journal of Oncology Nursing articles: Journey of a Patient With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Oncology Nursing Forum article: Facilitators of Multiple Myeloma Treatment: A Qualitative Study ONS books: Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) Multiple Myeloma: A Textbook for Nurses (third edition) ONS course: ONS Hematopoietic Stem Cell Transplantation™ ONS Huddle Cards: Financial Toxicity Hematopoietic Stem Cell Transplantation (HSCT) Monoclonal Antibodies ONS Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library American Society of Clinical Oncology (ASCO)–Ontario Health: Treatment of Multiple Myeloma Living Guideline International Myeloma Foundation: Clinical Trials Fact Sheets Clinical Trial Support Resource Library Multiple Myeloma Research Foundation resource: Treatments for Multiple Myeloma To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Typically for our first-line therapies, we use certain classes of drugs and some of them are proteasome inhibitors like bortezomib and carfilzomib. We also have IMiDs or immunomodulatory agents like thalidomide, lenalidomide, and pomalidomide. We have monoclonal antibodies, anti-CD38 monoclonal antibodies. Of course, we can never talk about treatment for myeloma without mentioning dexamethasone. It is an integral part of our treatment regimen. Most of our frontline therapies now are not just a single agent. They're not even doublets anymore. Typically, they're triplet therapies. And now in 2026, it's leaning more toward quadruplet therapies. By that, I mean you're taking a proteasome inhibitor, an immunomodulatory drug, dexamethasone, and an anti-CD38 monoclonal antibody all together to present patients with a good chance their induction therapy will lead to a good chance of them responding to treatment." TS 4:25 "[With] myeloma labs, there should be some indication after each cycle of therapy that the treatment is working. So, you don't have to do a whole myeloma panel, but maybe getting a monoclonal protein spike, maybe getting a free light chain assay, or maybe an immunoglobulin G or immunoglobulin A level, just to see if the treatment is working. So, those labs are crucial to determine whether the therapies are working. And again, the lab improvements usually correlate with the clinical presentation of the patient." TS 11:01 "There are active clinical trials ongoing with drugs like cell mods. Cell mods are the new oral anticancer agents for myeloma that have shown great promise with efficacy and safety profiles. And then there are other combinations that are showing a lot of promise. So, drugs that are already approved by the U.S. Food and Drug Administration (FDA). And I'm talking about pairing anti-CD38 monoclonal antibodies with bispecific T-cell engagers. If you do that, there has been some evidence that these combinations are very efficacious and responses are durable. And there are ongoing clinical trials and studies being done right now to see if these can be FDA-approved to pinpoint where they are as far as in comparison to other treatments." TS 20:10 "I always tell patients to try to participate in safe, and I want to stress safe, physical activity. So, I tell patients, the more you sit on the couch or you sit in the chair for most of the day, that unfortunately will make your pain worse. So, trying to get up and about and doing some physical activity, such as getting a physical therapy evaluation and a treatment program, no matter how passive or mild or gentle it is, can really help these patients with bone pain." TS 26:10 "I think it's important to realize that myeloma has had amazing advances in science, research and treatments. I think that all of these things coming together, all the science and clinical trials and everything like that, has led to a significant increase in overall survival of our patients, which ultimately is a great thing. We want patients to live longer and they're living longer with a very good quality of life. So, I think it's important to realize that myeloma is very well studied, very well researched, and it's still ongoing with many, many clinical trials." TS 36:04

"Radioimmunoconjugates work through a dual mechanism that combines immunologic targeting with localized radiation delivery. The monoclonal antibody components bind to specific tumor-associated antigens such as CD20, expressed on malignant B cells. Once found, the attached radioisotope delivers beta radiation directly to the tumor, causing DNA damage and cell death," Sabrina Enoch, MSN, RN, OCN®, CNMT, NMTCB (CT), theranostics clinical specialist at Highlands Oncology in Rogers, AR, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radioimmunoconjugates. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 30, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of radioimmunoconjugates in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 377: Creating and Implementing Radiopharmaceutical Policies and Procedures Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 298: Radiation Oncology: Nursing's Essential Roles ONS Voice articles: Interprofessional Collaboration Reduces Time to Neutropenia Antibiotic Administration Radiopharmaceuticals and Theranostics Offer New Options for Oncology Nurses to Transform Cancer Care Radiopharmaceuticals Pack a One-Two Punch Against Cancer Safety Is Key in Use of Radiopharmaceuticals Telehealth Has Value During Radiotherapy, Patients Say ONS Voice oncology drug reference sheets: Lutetium Lu 177 dotatate Lutetium Lu 177 vipivotide tetraxetan Radium 223 dichloride Sodium iodide-131 Strontium chloride Sr-89 ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: ONS/ONCC® Chemotherapy Immunotherapy Certificate™ ONS/ONCC® Radiation Therapy Certificate™ Clinical Journal of Oncology Nursing articles: Radiopharmaceutical Safety: Making It Easy Targeted Radionuclide Therapy: A Theranostic Approach to Cancer Therapy ONS Huddle Cards: Radiobiology Radiopharmaceuticals ONS Learning Libraries: Immuno-Oncology Radiation ONS Symptom Interventions for Prevention of Bleeding Drugs@FDA package inserts To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Radioimmunoconjugates are a specialized subset of radiopharmaceuticals designed to combine the specificity of monoclonal antibodies with the cytotoxic power of radiation. ... Early development focused on B-cell malignancies, particularly non-Hodgkin lymphoma." TS 1:51  "An important concept for nurses to understand is the crossfire effect, where radiation can affect nearby tumor cells, even though not every cell expressed has the target antigen. This helps explain why these agents can be effective even in heterogeneous tumors." TS 3:40 "At present, 90 Y-ibritumomab tiuxetan is the only radioimmunoconjugate approved by the U.S. Food and Drug Administration (FDA) in clinical use. Historically, iodine-131 tositumomab played a major role in establishing these therapy classes, but it's also useful to contrast radioimmunoconjugates with other radiopharmaceuticals, such as iodine-131 therapies, which a lot of places do at this time, used for thyroid diseases, or radium 223, used for metastatic prostate cancer. Unlike those agents, radioimmunoconjugates rely on antibody-mediated targeted rather than physiologic uptake or bone affinity." TS 4:55 "I just try to explain to [patients] that radiation exposure is like being next to a flame. The further you are away, the less heat you get, the less exposure you get. These patients can be radioactive for three days, seven days—it just depends on how fast they excrete it through their bodies with half-life exposure." TS 9:33 "While only one agent is currently approved, the principles established by radioimmunoconjugates continue to guide development for newer targeted radiopharmaceuticals. Emerging agents aim to improve targeting, reduce toxicity, and expand indications beyond hematologic malignancies. This evolution underscores the importance of nursing education in this rapidly changing field." TS 10:41 "Radioimmunoconjugates represent an important bridge between traditional oncology treatments and the future of targeted therapies. Oncology nurses play a vital role in ensuring safe delivery, patient understanding, and collaboration between multidisciplinary teams. So, it's very important to educate and also stay up to date on evidence-based practices." TS 13:12

Accreditation can feel overwhelming, but when done well, it's not a once-every-ten-years scramble. Dr. Angie Mund joins us this week to help reframe accreditation as an ongoing leadership practice that shapes program culture, faculty development, and student outcomes. Drawing on decades of experience as a program director, department chair, and national leader, Dr. Mund explains what's usually true long before a successful COA site visit ever begins.  Here's some of what you'll hear in this episode:

Send us a textWe are back! In this episode, we sit down with Marcia Wheeler, our Director of Assessment and Accreditation and the force behind the New Faculty Institute, to pull back the curtain on what “assessment” and “accreditation” actually look like on a real college campus. Expect practical tips you can use right away, the most common myths that stress faculty out for no reason, and a few laugh out loud moments that feel way too familiar if you have ever battled Canvas, deadlines, or a department meeting agenda. If you want the behind the scenes playbook for Access, Assess, and Address, plus a fresh boost of confidence for teaching and improving without drowning in paperwork, this one is for you.

In this insightful episode, Grayson Harris sits down with Bennett Weiner, the newly appointed CEO of the BBB Wise Giving Alliance (Give.org).As we move through 2025 and look toward 2026, the landscape of philanthropy is shifting rapidly. Bennett shares his expertise on the critical importance of nonprofit transparency, the "evolving" nature of accountability standards, and how organizations can navigate a world where AI bots may soon outnumber humans.Key TakeawaysThe Power of Accreditation: Unlike rating systems that use arbitrary letter grades, Give.org focuses on a 20-standard evaluation process covering governance, finances, and privacy.The Information Gap: A startling 2025 survey revealed that only 32% of Americans were aware of federal grant reductions. Nonprofits must proactively educate their donors rather than assuming they know the challenges.The "Founder Syndrome" Risk: Bennett discusses the importance of objective governance and why the transition from a founder-led "passion project" to an adult, governed organization is vital for long-term survival.AI Policy is Non-Negotiable: With the rise of generative AI, nonprofits need clear policies on oversight and accuracy verification to maintain trust. ---------------------------About Charity ChargeCharity Charge is a financial technology company serving the nonprofit sector. From the Charity Charge Nonprofit Credit Card to bookkeeping, gift card disbursements, and state compliance, we help mission-driven organizations streamline operations and stay financially strong. Learn more at charitycharge.com.

"The United States does not have a national cancer registry. We have a bunch of state registries. Some of those registries do collaborate and share information, but the issue is the registries that do exist typically do not report cancer by occupation. So, we cannot get our arms around the potential work-relatedness of the health outcome given the current way the state registries collect information. What we're trying to set up, is a way to make what is currently an invisible risk, visible," ONS member Melissa McDiarmid, MD, MPH, DABT, professor of medicine and epidemiology and public health director of the division of occupational and environmental medicine at the University of Maryland School of Medicine in Baltimore, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the University of Maryland School of Medicine Hazardous Drug Safety Center Exposure Registry. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 23, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the incidence of hazardous drug exposure and the tracking and reporting of healthcare worker exposures. Episode Notes  Complete this evaluation for free NCPD. University of Maryland School of Medicine Hazardous Drug Safety Center Exposure Registry information sheet ONS Podcast™ episodes: Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 308: Hazardous Drugs and Hazardous Waste: Personal, Patient, and Environmental Safety Episode 209: Updates in Chemo PPE and Safe Handling ONS Voice articles: Hazardous Drug Surface Contamination Prevails, Despite More Diligent PPE National Hazardous Drug Exposure Registry Safeguards Oncology Professionals NIOSH Releases Its 2024 List of Hazardous Drugs Safe Handling—We've Come a Long Way, Baby! Strategies to Promote Safe Medication Administration Practices Surfaces in Patient Bathrooms Often Contaminated With HDs, Despite Use of Plastic-Backed Pads ONS books: Safe Handling of Hazardous Drugs (fourth edition) Safe Handling of Hazardous Drugs Quick Guide™ ONS course: Safe Handling Basics Clinical Journal of Oncology Nursing articles: Hazardous Drug Exposure: Case Report Analysis From a Prospective, Multisite Study of Oncology Nurses' Exposure in Ambulatory Settings Personal Protective Equipment Use and Surface Contamination With Antineoplastic Drugs: The Impact of the COVID-19 Pandemic Sequential Wipe Testing for Hazardous Drugs: A Quality Improvement Project The Use of Plastic-Backed Pads to Reduce Hazardous Drug Contamination Oncology Nursing Forum articles: Ensuring Healthcare Worker Safety When Handling Hazardous Drugs Factors Influencing Nurses' Use of Hazardous Drug Safe Handling Precautions Other ONS resources: ONS Safe Handling of Hazardous Drugs Quick Guide Introduction to Safe Handling Huddle Card Safe Handling of Hazardous Drugs Learning Library Hematology/Oncology Pharmacy Association (HOPA) course: Safe Handling of Hazardous Drugs National Institute for Occupational Safety and Health (NIOSH) List of Hazardous Drugs in Healthcare Settings, 2024 To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We thought that in order to answer some of the unclear questions about health risk, we would set up an exposure registry, in this case, for oncology personnel who handle the drugs. This would then create a cohort that we could ask questions to. For example, we could try to characterize whether there is a cancer excess in this group. Or characterize the reproductive abnormalities in excess that people are experiencing." TS 6:21 "It's sort of counterintuitive that the healthcare industry, whose mission itself is care of the sick, is a high-hazard industry. We typically think about the risk as being from infectious diseases, and certainly we've all lived in our practice lifetime through some examples of that. Even before COVID-19, some of us were doing preparation for Ebola and that sort of thing. So, we're kind of used to that. But the hazards that you kind of grew up with, we've routinized or normalized handling group one, human carcinogens, which a number of these drugs are—it's just something we do every day. Well, it is, but we have to do it with respect and with care every day. And I think sometimes in that routineness of it, we have sort of lost sight of the vigilance that we need to maintain." TS 11:19 "It's very easy in the life cycle of a drug in an organization to do something that doesn't just impact you, but unknowingly, you've contaminated a surface for somebody who comes behind you. Who maybe doesn't have plastic protective equipment on because something that got contaminated shouldn't have been contaminated in the first place. If we could all be thinking of it as more of a team sport, especially in terms of safe handling, that our disposition and drug handling affects not just us and our health, but those of our colleagues." TS 24:47 "For the job history pieces, we ask what year you started, what year you stopped, and we ask about estimations of handling. So we'll be able to come up with either a duration or some kind of metric for the intensity and duration of your handling history, which will then permit us to sort the population who completed the survey into sort of low, medium, high. And we'll see whether the health outcomes that are being reported are influenced by that drug handling history." TS 27:45 "The idea that we aren't exposed to the same therapeutic dose we give to our patients is absolutely true. However, the dosing schedule to them versus us is very different, and we are exposed frequently, if not daily, to very small concentrations. They don't reach a cytotoxic dose necessarily, but we do know from a lot of studies that either ourselves or our colleagues are taking up drug from contaminated work environments. And you've probably seen there is an awful lot of intermediate evidence looking at genotoxic insult in pharmacists and nurses who handle the drugs. So clearly we're showing uptake and we're showing that there are biologically plausible, concerning measures that are taking place in us. So, I think that we need to come back and circle around the idea that we need to have deep respect for the toxicity of these agents." TS 35:03

Success isn't just about the medals. In this episode, Kirk Behrendt brings back Dr. Amanda Seay, president of the AACD, and Dr. Zach Sisler, board chair of the AACD, to share their journeys and lessons of the accreditation process and the importance of investing in yourself for your future. To learn what success could look like for you, listen to Episode 999 of The Best Practices Show!Learn More About Dr. Seay & Dr. Sisler:Join Dr. Seay on Facebook: https://www.facebook.com/DrAmandaSeayFollow Dr. Seay on Instagram: https://www.instagram.com/dramandaseayJoin Dr. Sisler on Facebook: https://www.facebook.com/SmilesBySislerFollow Dr. Sisler on Instagram: https://www.instagram.com/dr_zachsislerRegister for the AACD Scientific Session (April 16-18, 2026): https://www.aacdconference.com/event/1a1b9fe4-2097-4006-b107-822d4da3654b/main-menuMore Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store:

You're listening to American Ground Radio with Louis R. Avallone and Stephen Parr. This is the full show for January 19, 2026. 0:30 A church service in St. Paul, Minnesota was violently disrupted—and this wasn’t activism or a protest gone too far. It was a warning. In this explosive segment, we break down the shocking invasion of a house of worship by far-left agitators, the terror it caused for families and children, and why this moment signals a growing threat to religious freedom in America. We unpack how the First Amendment actually works, why “hands up, don’t shoot” was invoked inside a church despite being a proven falsehood, and how comparing this disruption to Jesus “flipping tables” completely misses the truth of Scripture. From ancient Rome to Soviet Russia to modern-day China, history shows what happens when mobs or governments decide which beliefs are acceptable—and why the Founders put freedom of worship at the very top. 9:30 Plus, we cover the Top 3 Things You Need to Know. On Sunday, anti-ICE agitators stormed a church in Minneapolis, mid service. President Trump is suing JP Morgan Chase bank for de-banking him. Elon Musk has made his largest political donation in a US Senate Campaign Ever. 12:30 Get Performlyte from Victory Nutrition International for 20% off. Go to vni.life/agr and use the promo code AGR20. 13:00 We break down the meaning of “debanking” — and why it should alarm anyone who claims to oppose oligarchy, fascism, or unaccountable power. What sounds like a boring financial term is actually a quiet but devastating weapon: banks cutting people off from basic financial services not for fraud or criminal behavior, but for holding the “wrong” political views. No warning. No due process. No appeal. 16:00 We got a question in for our American Mamas: Teri Netterville and Kimberly Burleson. Is modeling still a real career in the age of Instagram, influencers, and AI? From Melania Trump’s supermodel past to today’s social-media-driven fame, we break down how the industry has completely flipped. Runway models may still walk the catwalk, but many admit they’re broke. Meanwhile, Instagram models and influencers—with filters, cosmetic surgery, and massive followings—are the ones actually making money, getting brand deals, and shaping culture. But is this shift healthier… or worse? We dig into body image, “body positivity,” filters, Ozempic, and the hypocrisy of woke celebrity culture that preached self-love—until a miracle weight-loss drug showed up. Whether it’s runway modeling or social media influencing, tying your livelihood to your appearance comes at a cost. If you'd like to ask our American Mamas a question, go to our website, AmericanGroundRadio.com/mamas and click on the Ask the Mamas button. 23:00 We circle back to the Minneapolis church that was stormed by left-wing ICE protesters—and this time the conversation gets even more alarming. What started as agitators chanting “hands up, don’t shoot” inside a house of worship quickly turns into something far more dangerous: elected officials openly encouraging more churches to be targeted. 26:00 Florida just dropped a legal bombshell—and it could permanently reshape legal education in America. We break down the Florida Supreme Court’s decision to strip the American Bar Association of its monopoly power over law school accreditation, a role the ABA has held nationwide for decades. Why does this matter? Because the court says the ABA stopped acting like a neutral standards body and started acting like a political enforcer—pushing DEI mandates and ideological compliance instead of merit-based legal training. Florida’s ruling opens the door for alternative accrediting bodies and puts access, affordability, academic freedom, and non-discrimination back at the center of legal education. And Florida isn’t alone. Texas has already kicked the ABA out entirely, placing accreditation authority directly under the state Supreme Court. Now other conservative states like Ohio and Tennessee are lining up to follow suit, setting the stage for a clear red-state vs. blue-state divide in how future lawyers are trained. 32:00 Get Prodovite Plus from Victory Nutrition International for 20% off. Go to vni.life/agr and use the promo code AGR20. 32:30 Your car isn’t just getting you from point A to point B anymore—it’s quietly tracking you the entire way. We break down how modern vehicles have become rolling surveillance machines, recording your location history, driving habits, and even who’s riding with you—and yes, automakers can legally sell much of that data. We dig into a new push in Congress to put drivers back in control. Representative Eric Burlison and Senator Mike Lee have reintroduced the Auto Data Privacy and Autonomy Act, a bill designed to give vehicle owners the right to see what data is being collected, stop the tracking, delete stored information, and opt out of having their personal driving data sold. 35:30 On Martin Luther King Jr. Day, we go back to something you don’t hear quoted nearly enough—a powerful early-1960s sermon from Dr. King on the Good Samaritan and the limits of government power. Long before today’s culture wars, MLK warned that laws can enforce justice, but they can’t manufacture compassion, morality, or love. We connect King’s words to a hard truth facing America right now: the Constitution assumes a moral people—it doesn’t create one. You can outlaw theft, but you can’t legislate empathy. You can regulate behavior, but you can’t command the heart. As King put it, “man-made laws assure justice, but a higher law produces love.” 39:30 We take a hard look at Hollywood hypocrisy after Ellen DeGeneres—now living comfortably on an $18 million farm in England—publicly praised the activists who stormed a church during a live worship service. We break down why this wasn’t “peaceful protest,” but intimidation and trespass, and why nobody gets hurt for simply protesting—you get hurt when you confront police, disrupt worship, or violate the rights of others. 41:30 And we finish off with a celebrity and philanthropist who will make you say, "Whoa!" Follow us: americangroundradio.com Facebook: facebook.com / AmericanGroundRadio Instagram: instagram.com/americangroundradioSee omnystudio.com/listener for privacy information.

Are you looking for CPD that actually fits into real life while still deepening your confidence and capability as a coach? As we recorded this episode, we found ourselves reflecting on the growing gap between what coaches need from professional development and what most CPD programmes actually deliver. We know how busy life is. We know how difficult it can be to commit to long programmes with heavy time demands. And we also know how frustrating it feels to learn theory without truly knowing how to apply it in real coaching conversations. This episode is our response to that reality. We introduce our Done for You 2026 CPD programme, the How To Series, a bite size, practical and accredited professional development journey designed specifically around the topics coaches face every day. Each session is rooted in a popular Coaching Crowd podcast episode and translated into a facilitated, interactive learning experience that bridges the gap between insight and action. Across the conversation, we talk openly about why this series matters to us. We share how the idea was born from listening closely to our community and noticing which podcast episodes consistently resonate, such as coaching confidence, fear, burnout, overwhelm and uncertainty. These are not abstract topics. They are live issues showing up in coaching rooms week after week. Each 'How To' session is a two and a half hour live workshop that includes a focused teaching summary, a practical coaching activity, live demonstrations, peer practice, feedback, and reflective discussion. We wanted to create CPD that feels immediately useful, supports skill integration, and builds real coaching confidence. This is learning you can take straight into your next client session. We also reflect on accessibility. This series is designed for qualified coaches, leaders, managers and those using coaching skills in their work. It is accredited, offering CCEs, while remaining financially accessible and flexible. Coaches can attend individual sessions or commit to the full year and have their 2026 CPD fully mapped out in advance. Throughout the episode, we talk about community, experimentation and our desire to create a shared learning space where coaches can connect, practise, ask real questions and grow together. This is about more than content. It is about confidence, capability and belonging within the coaching profession.   Timestamps: 00:00 Introduction and why this episode matters 00:57 Why bite size CPD works for busy coaches 01:26 What is included in each How To session 01:55 Overview of the 10 coaching topics 02:24 Creating a full CPD plan for 2026 02:51 Accreditation, CCEs and pricing structure 03:46 Why these topics resonate with coaches 04:06 Who this CPD is designed for 05:04 How to access the programme and resources 06:02 Community, connection and future possibilities 07:43 Limited time offer and enrolment window 08:33 Who can attend and who it is suitable for 09:57 Live demos and experiential learning 12:21 Practice, feedback and reflective integration 13:43 Flexibility, value and long term impact 15:20 Closing reflections and invitation   Key Lessons Learned: CPD is most effective when it supports immediate application in real coaching conversations Bite size learning can deliver depth when it is well designed and facilitated Coaches value live demonstrations as a bridge between theory and practice Accessibility and affordability increase engagement and consistency with professional development Community and shared learning strengthen confidence, identity and capability as a coach   Links and Resources: https://igcompany.co.uk/howto   Keywords: Coaching CPD 2026, accredited coaching CPD, bite size coaching training, coaching professional development, coaching skills development, coaching confidence training, coaching burnout CPD, live coaching workshops, coach accreditation CCEs, The Coaching Crowd podcast

One Year On: Alex Gulland's Journey into Practice – Confidentiality in Counselling Case Studies In Episode 362 of the Counselling Tutor Podcast, your hosts Rory Lees-Oakes and Ken Kelly take us through this week's three topics: Firstly, in ‘Ethical, Sustainable Practice', we explore working with clients who have a psychiatric diagnosis, considering how to approach this work ethically, including navigating risk, understanding medication, and maintaining person-centred care. Then in ‘Practice Matters', Rory catches up with Alex Gulland, a year after she qualified, to hear what the transition from student to practitioner has really been like – from building a client base to discovering a passion for equine-assisted therapy. And finally in ‘Student Services', Ken and Rory explore how to protect client confidentiality when writing case studies – including anonymisation techniques and data protection guidance. Sarah Henry joins to share her frontline insights into balancing academic and ethical responsibilities. Working with Clients Who Have a Psychiatric Diagnosis [starts at 03:17 mins] In this section, Rory and Ken explore working with clients who have a psychiatric diagnosis, unpacking the complexities of staying within professional competence while offering relational, therapeutic support. Key points discussed include: Understanding diagnoses like bipolar disorder or schizophrenia helps reduce fear and supports ethical, informed practice. Therapists must see the person first – not the label or diagnosis – and listen to what the client needs from therapy. Medication, risk, and involvement with community mental health teams should be explored during initial assessments. Supervision is essential when working with clients who have complex mental health needs, especially during episodes of active distress or psychosis. Counsellors should seek CPD to increase confidence and competence in this area, and avoid making assumptions about diagnosis severity. One Year On: Alex Gulland's Journey into Practice [starts at 26:53 mins] In this week's ‘Practice Matters', Rory reconnects with Alex Gulland to hear how her first year as a qualified counsellor has unfolded – from business decisions to developing her niche. Key points from this conversation include: Building a client base takes time and persistence; marketing and directory presence matter. Accreditation and professional registration offer reassurance but are not always decisive factors for clients. Combining freelance roles in training with private practice has provided income and valuable experience. Alex shares how equine-assisted therapy has become a core part of her practice, offering creative, non-verbal connection. Continued learning, especially in areas like attachment theory and shadow work, has been central to her growth. Confidentiality in Counselling Case Studies [starts at 55:18 mins] In this section, Rory and Ken provide a detailed guide on how to write case studies while protecting client identity – a key consideration in counselling education. Key points include: Use anonymisation techniques such as pseudonyms, vague job titles, and generalised locations to remove identifying details. Only include information directly relevant to the assignment question – avoid unnecessary specifics or rare events. Gain informed consent where possible, and understand awarding body and agency policies on client data use. Refer to BACP guidance, ICO anonymisation principles, and supervisor support to ensure ethical compliance. Sarah Henry emphasises how students can reflect on their motivations and ensure they write responsibly while still demonstrating learning. Links and Resources Counselling Skills Academy Advanced Certificate in Counselling Supervision Basic Counselling Skills: A Student Guide Counsellor CPD Counselling Study Resource Counselling Theory in Practice: A Student Guide Counselling Tutor Training and CPD Facebook group Website Online and Telephone Counselling: A Practitioner's Guide Online and Telephone Counselling Course

"[Multiple myeloma] is very treatable, very manageable, but right now it is still considered an incurable disease. So, patients are on this journey with myeloma for the long term. It's very important for us to realize that during their journey, we will see them repeatedly. They are going to be part of our work family. They will be with us for a while. I think it's our job to be their advocate. To be really focused on not just the disease, but periodically assessing that financial burden and psychosocial aspect," Ann McNeill, RN, MSN, APN, nurse practitioner at the John Theurer Cancer Center at Jersey Shore University Medical Center in Neptune, NJ, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about multiple myeloma. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 16, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the pathophysiology and diagnosis of multiple myeloma. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 332: Best Nursing Practices for Pain Management in Patients With Cancer Episode 256: Cancer Symptom Management Basics: Hematologic Complications Episode 192: Oncologic Emergencies 101: Hypercalcemia of Malignancy ONS Voice articles: AI Multiple Myeloma Model Predicts Individual Risk, Outcomes, and Genomic Implications Cancer Mortality Declines Among Black Patients but Remains Disproportionately High Financial Navigation During Hematologic Cancer Saves Patients and Caregivers $2,500 Multiple Myeloma: Detecting Genetic Changes Through Bone Marrow Biopsy and the Influence on Care Multiple Myeloma Prevention, Screening, Treatment, and Survivorship Recommendations Nurse-Led Bone Marrow Biopsy Clinics Truncate Time for Testing, Treatment Diagnose and Treat Hypercalcemia of Malignancy ONS books: BMTCN® Certification Review Manual (second edition) Multiple Myeloma: A Textbook for Nurses (third edition) Clinical Journal of Oncology Nursing articles: African American Patients With Multiple Myeloma: Optimizing Care to Decrease Racial Disparities Music Intervention: Nonpharmacologic Method to Reduce Pain and Anxiety in Adult Patients Undergoing Bone Marrow Procedures Other ONS resources: Financial Toxicity Huddle Card Hypercalcemia of Malignancy Huddle Card Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library American Cancer Society article: What Is Multiple Myeloma? Blood Cancer United educational resources page International Myeloma Foundation homepage Myeloma University homepage Multiple Myeloma Research Foundation (MMRF) article: Understanding Multiple Myeloma To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Epidemiologically, myeloma is a cancer of older adults. The median age is about 69. It is more common in men than women. It's a ratio of about three men to two women that are diagnosed. It is much more common in people of African American descent with increasing global incidence linked to aging populations. Although, the highest rates are in high-income countries. So, if we look at some of the risk factors, and several have been identified, including MGUS. MGUS is a benign precursor of myeloma, and it stands for monoclonal gammopathy of undetermined significance. Older age is also a risk factor, although we do see patients that are younger who are diagnosed with myeloma." TS 1:54 "Bone pain, specifically in the back, and fatigue, are very common symptoms that relate to things that are going on behind the scenes with myeloma. But also, patients can be bothered by frequent and long-lasting infections. So, they find that they get sick more frequently than their family and friends, and they take a longer time to recover. That could also be a presenting sign. I think there can be some presenting signs and symptoms related to electrolyte abnormalities, especially in later stages. They might be nauseated, vomiting, or constipated. Also, signs and symptoms related to cytopenias. You have to remember that this is a bone marrow cancer. So, we do have some problem with development of normal blood cells. So, we can see not only infections, but bleeding issues related to thrombocytopenia and factors related to anemia from low red blood cell counts." TS 7:15 "About 20%–25% of our patients who are diagnosed are asymptomatic. They have no symptoms. They're living their lives, they're going to work or they're traveling, playing golf on the weekends, taking care of their children or grandchildren. They are just living their lives. And at times, they go to the primary care physician and then they're referred to a hematologist-oncologist, and they're pretty surprised when they're sent to a cancer center. The way they are diagnosed in this matter is that their routine lab work, the complete blood cell count may be normal, there may be some slight differences in their hemoglobin. But what we see in the chemistry, the complete metabolic panel, is an elevation in their total protein and or an elevation of the total globulins." TS 9:22 "The bone marrow biopsy serves many purposes. You want to determine the percentage of bone marrow plasma cells. So, you want to get the degree of plasmacytosis. And then you want to do really specific tests on those plasma cells. So, you want to isolate the malignant plasma cells and determine, via analysis. So, we do the karyotype, chromosomal studies, fluorescence in situ hybridization (FISH) studies, immunohistochemistry studies, and molecular studies. All of these studies are looking for specific genetic changes in the myeloma cells—looking for translocations or deletions. And it's very important to get that information because we can put patients in a category of having standard-risk disease versus high-risk disease. And that can give us a better picture of what this patient's journey with myeloma may look like." TS 13:41 "When I used to work in lymphoma, I spoke with the physicians who were lymphoma specialists, and they said that they foresee a future in having these assays that detect circulating tumor cells actually take the place of imaging studies like restaging positron-emission tomography (PET), computed tomography (CT) scans. So, it's really amazing, these tests that are on the market now and maybe not as widespread as we'd like, but there's a lot of nice assays out there that will become more popular and used more commonplace in the future that I think are going to help identify myeloma more precisely. ... If you think about myeloma, even with measurable residual disease (MRD), MRD for leukemia, for lymphoma, you take a blood sample, you test it for MRD. For myeloma, you need a bone marrow biopsy. You need a bone marrow sample. You can't do MRD on a blood sample for myeloma. Not yet. But if we perfect these assays and we can eventually detect this, then you're looking at a whole new ballgame. You can even perfect your MRD testing as well. So, it's a very exciting time for some of these heme malignancies." TS 28:09

Dr Karen Collins-Adams, SLPS School Board President, joins Megan Lynch following a move from the state of Missouri Department of Education to lower the district's status of accreditation to provisional. She points out that changes in school board leadership resulted in a delay to an audit that was due. She says the board is working to get that report in by the end of January.

As we kick off the new year, all four hosts are back for a discussion that every nurse anesthesia program will face at some point. We're sitting down together for a candid, experience-driven conversation about what accreditation really looks like from the inside, whether you're a program director, faculty member, or educator preparing for your first review. Drawing from multiple accreditation cycles, on-site visits, and self-study efforts, the panel discusses what works, what surprises programs, and why accreditation should be viewed as a measure of compliance, not a judgment of educational quality. We understand how overwhelming the process can feel at times, but getting guidance and resources from peers can help alleviate some of the pressure. Here's some of what you'll hear in this episode:

Looking for ways to improve your care and support of renal patients? Join the co-hosts and special guest Linda Brown for a candid conversation, personal stories, and tips for renal patient care. From fluid and electrolyte balance to med dosing, dialysis coordination, red-flag assessment, and death, this is one episode you won't want to miss. (AMSN Members Earn 0.5 CE Hours*)   * This episode is eligible for 0.5 contact hours for AMSN members who listen to the episode and submit a completed evaluation through the online library. None of the individuals with the ability to control the content of this episode have any relevant financial relationships with ineligible companies to disclose. The Academy of Medical Surgical Nurses is an accredited provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.   SPECIAL GUEST   Linda S. Brown BSN, RN-BC Linda S. Brown is a Medical-Surgical Board Certified registered nurse with over four decades of nurse experience in the hospital setting, particularly in renal patient care. She received four Daisy Awards for extraordinary nursing and patient-centered care and the March of Dimes Medical-Surgical Nurse of the Year. She was recently recognized as one of the AJC Celebrating Nurses Honorees. Her passion for caring and making a difference has always been her hallmark in providing an exceptional nursing care experience. Over the years, Linda has recognized that balancing her nursing career with self-care is essential for her longevity in nursing.   MEET OUR CO-HOSTS Samantha Bayne, MSN, RN, CMSRN, NPD-BC is a nursing professional development practitioner in the inland northwest specializing in medical-surgical nursing. The first four years of her practice were spent bedside on a busy ortho/neuro unit where she found her passion for newly graduated RNs, interdisciplinary collaboration, and professional governance. Sam is an unwavering advocate for medical-surgical nursing as a specialty and enjoys helping nurses prepare for specialty certification.    Kellye' McRae, MSN-Ed, RN is a dedicated Med-Surg Staff Nurse and Unit Based Educator based in South Georgia, with 12 years of invaluable nursing experience. She is passionate about mentoring new nurses, sharing her clinical wisdom to empower the next generation of nurses. Kellye' excels in bedside teaching, blending hands-on training with compassionate patient care to ensure both nurses and patients thrive. Her commitment to education and excellence makes her a cornerstone of her healthcare team.   Marcela Salcedo, RN, BSN is a Floatpool nightshift nurse in the Chicagoland area, specializing in step-down and medical-surgical care. A member of AMSN and the Hektoen Nurses, she combines her passion for nursing with the healing power of the arts and humanities. As a mother of four, Marcela is reigniting her passion for nursing by embracing the chaos of caregiving, fostering personal growth, and building meaningful connections that inspire her work.   Eric Torres, ADN, RN, CMSRN is a California native that has always dreamed of seeing the World, and when that didn't work out, he set his sights on nursing.  Eric is beyond excited to be joining the AMSN podcast and having a chance to share his stories and experiences of being a bedside medical-surgical nurse.   Maritess M. Quinto, DNP, RN, NPD-BC, CMSRN is a clinical educator currently leading a team of educators who is passionately helping healthcare colleagues, especially newly graduate nurses. She was born and raised in the Philippines and immigrated to the United States with her family in Florida. Her family of seven (three girls and two boys with her husband who is also a Registered Nurse) loves to travel, especially to Disney World. She loves to share her experiences about parenting, travelling, and, of course, nursing!   Sydney Wall, RN, BSN, CMSRN has been a med surg nurse for 5 years. After graduating from the University of Rhode Island in 2019, Sydney commissioned into the Navy and began her nursing career working on a cardiac/telemetry unit in Bethesda, Maryland.  Currently she is stationed overseas, providing care for service members and their families.  During her free time, she enjoys martial arts and traveling. 

This December 2025 roundtable conversation with leaders from the International Union of Painters and Allied Trades (IUPAT) explores the vital role of certifications in industrial painting, as well as areas in which a trained and certified workforce can boost the coatings industry. Topics on this sponsored episode include modern project requirements, certifications, and the industry's future; QP contractor requirements; how contractor accreditation can help ensure quality and protect investments; and the IUPAT's important role in raising the bar for industry standards.

In this episode Beauty School Bobbi discusses the importance of maintaining a positive outlook in the beauty industry, especially in light of the negativity often found online. She emphasizes the need for beauty school students to focus on their education, the significance of accreditation, and the value of building a supportive community. Bobbi also addresses the impact of social media on perceptions of beauty schools and encourages students to handle challenges with professionalism and positivity.   Takeaways The beauty industry should focus on spreading positivity. Negativity online can discourage potential beauty students. Accreditation ensures quality education in beauty schools. Students should make the most of their beauty school experience. Professionalism is essential for success in the beauty industry. Building a supportive community is crucial for students. Conflict resolution skills are important in the workplace. Social media can amplify negative perceptions of beauty schools. It's okay to change career paths if needed. Encouraging a positive mindset can improve the industry overall.   Chapters 00:00 Introduction to Positivity in the Beauty Industry 03:10 Addressing Negativity Online 06:02 The Importance of Accreditation in Beauty Schools 08:53 Navigating Challenges in Beauty School 12:03 Building a Supportive Community 14:59 Professionalism and Online Presence 17:59 Conflict Resolution and Moving Forward 20:49 The Role of Social Media in Perception 24:04 Encouraging a Positive Mindset 26:51 Finding Your Path in the Beauty Industry 29:48 Conclusion and Call to Action   www.beautyschoolbobbi.com www.beautyandstylenetwork.com   Follow Beauty and Style Network: @beautystylenet Beauty School Bobbi: @beautyschoolbobbi

"Referring patients to audiology early on has shown dramatic reduction in hearing loss or complications because the audiologist can really see where were they at before they started chemotherapy, where were they at during, if they get an audiogram during their treatment. And then after treatment, it's really important for them to see an audiologist because this is really a survivorship journey for them. And as nurses, the 'so what': We are the first line of defense," ONS member Jennessa Rooker, PhD, RN, OCN®, director of nursing excellence at the Tampa General Hospital Cancer Institute in Florida, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about ototoxicity in cancer care. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 9, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the management of ototoxicity after chemotherapy treatment. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ Cancer Symptom Management Basics series ONS Voice articles: Oncology Drug Reference Sheet: Cisplatin Oncology Drug Reference Sheet: Carboplatin Oncology Drug Reference Sheet: Oxaliplatin FDA Approves Sodium Thiosulfate for Cisplatin-Associated Ototoxicity in Pediatric Patients ONS book: Clinical Manual for the Oncology Advanced Practice Nurse (fourth edition) American Cancer Society resources: 4 Causes of Hearing Problems for Cancer Survivors Cancer Survivors Network American Speech-Language-Hearing Association (ASHA) Hearing Loss: An Under-Recognized Side Effect of Cancer Treatment Embedded Ear Care: Audiology on the Cancer Treatment Team American Society of Clinical Oncology (ASCO) Annual Meeting abstract: Innovative Infusion Center Assessments of Chemotherapy-Induced Neurotoxicities: A Pilot Study Supporting Early and Routine Screenings as Part of Survivorship Programs Children's Oncology Group supportive care endorsed guideline: Prevention of Cisplatin-Induced Ototoxicity in Children and Adolescents With Cancer: A Clinical Practice Guideline Ear and Hearing article: Roadmap to a Global Template for Implementation of Ototoxicity Management for Cancer Treatment International Ototoxicity Management Group (IOMG) IOMG Wikiversity page Shoebox hearing assessments World Health Organization initiative: Make Listening Safe To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "At different pitches, the eardrums move faster or slower, signaling the inner ear, or the cochlea—the thing that looks like a snail in the pictures. The cochlea has fluid and hair cells inside of it that receive movements from the eardrum. The hair cells change the movement into electrical signals that actually go to the auditory nerves or the cranial nerve VIII." TS 2:15 "Ototoxicity is an umbrella term for some sort of exposure to a toxin that causes damage to the inner ear. These toxins can be in the environment, such as loud or different noises, or they can be from medications, including antibiotics or commonly cancer treatments, such as radiation chemotherapy. Some common chemotherapies can be platinum-based chemotherapies like cisplatin or carboplatin. And then what patients are experiencing if they have ototoxicity can be hearing loss." TS 3:15 "The hypothesized mechanism of action is that the chemicals like the platinum compound in cisplatin … that platinum compound travels through our bloodstream. Since chemotherapy is systemic, it'll go to the inner ear, and it gets stuck there by binding to the cellular DNA in that cochlea, or that snail-looking image. That initiates the release of the reactive oxygen species, which are really trying to help clean it out, but releases such high levels that it ends up causing damage to those inner ear hairs. These inner ear hairs cannot regenerate themselves, so then they're permanently damaged. And remember we said that those hairs send electrical signals to the brain that recognize sound. So that function is permanently gone once those hair cells are damaged." TS 7:10 "I definitely think this is a huge interdisciplinary collaborative effort. As nurses and advanced providers, we're assessing and providing education. Our medical oncologists are doing those dose modifications and submitting those audiology referrals. The radiation oncologists are very important to know about this—maybe dose localization awareness. Maybe they do some changes with the doses. And then our audiologists and [ear, nose, and throat physicians], they can do that diagnostic confirmation and any rehabilitation measurements and really monitor them throughout their journey as well. And nurse navigators play a huge part in making sure those patients get those referrals, because a lot of the time the audiologists aren't in the cancer clinic, so they may have to go to another location or may need help coordinating with all their appointments that they have." TS 22:28 "We had a really innovative way of monitoring the hearing that a couple other studies have also tested. It's a remote point-of-care hearing screen. It was on [a tablet] with calibrated headphones. And then it's a paid-for subscription to an audiology testing platform. … Myself, along with a couple of other nurses, were trained how to use this testing device with the tablet and the headphones and the software program. And it was a quick down-and-dirty portable hearing assessment for patients. So anyone who was new to cisplatin, never gotten cisplatin treatment before, was enrolled into the study, and they received a hearing test every time that they came for chemo, and we gave it to them during their hydration." TS 28:59  

The Business Council of Westchester kicked off the year in style with its BCW New Year Blast, held on Wednesday, January 7th at the Greentree Country Club in New Rochelle. This signature seasonal networking event brought members together for an energetic evening filled with great music, delicious food, and refreshing beverages, all set against a warm and welcoming atmosphere. It was a wonderful way to launch 2026, offering the perfect opportunity to celebrate with fellow members, spark new business connections, and strengthen existing relationships. The New Year Blast once again highlighted the power of community, collaboration, and connection that defines BCW.Westchester Talk Radio was on hand to capture the energy of the evening, highlighting the connections, conversations, and sense of community that define BCW events. Host Bob Marrone caught up with Jennifer Flowers, Founder and CEO of Accreditation Guru, to talk about Accreditation Guru and its role in helping organizations navigate complex accreditation processes. She shared how her team supports healthcare and education organizations in achieving compliance and excellence.

In this season finale of Metrology Today, Ryan and Henry wrap up Season 4 with a look back at the conversations, guests, and themes that defined the year — and a preview of what's coming next. This season featured consultants, assessors, industry leaders, and practitioners from across metrology, testing, manufacturing, and quality, covering topics including: Accreditation and assessment realities Decision rules and uncertainty Buying the wrong equipment — and the real cost of rework and false decisions Testing, production, and measurement beyond the lab Why metrology education needs to meet people where they are The episode also previews Season 5, which will introduce topic-focused educational podcasts and bonus episodes designed to support technicians, managers, and organizations making real measurement decisions. Whether you're deep in metrology or responsible for measurement outcomes at a higher level, this episode ties the season together and sets the stage for what's ahead.

BBB accreditation can be confusing for local business owners. Some see it as a powerful trust signal, while others question whether it is worth the cost. In this episode, we break down what BBB accreditation actually means, the pros and cons of getting accredited, and when it makes sense for a local business to invest in it.If you want a clear, practical perspective to help you decide whether BBB accreditation fits your business and your customers, this episode will help you make that call with confidence.This episode is for educational purposes only and is not affiliated with, endorsed by, or sponsored by the Better Business Bureau.About Adam Duran, Digital Marketing Expert⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Local SEO in 10⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ is helmed by Local SEO expert Adam Duran, director of Magnified Media. With offices in San Francisco, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Los Angeles⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ & Walnut Creek, California, Magnified Media is a ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠digital marketing agency⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ focused on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠local SEO for businesses⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠marketing strategy⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠national SEO⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠website design⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠and qualified customer lead generation for companies of all sizes.Magnified Media helps companies take control of their marketing by:• getting their website seen at the top of Google rankings,• getting them more online reviews, and• creating media content that immediately engages with their audience.Adam enjoys volunteering with several community-based non-profits, hiking and BJJ.About Jamie Duran, host of Local SEO in 10Local business owner Jamie Duran is the owner of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Solar Harmonics⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Northern California⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠'s top-rated solar company, which invites its customers to “Own Their Energy” by purchasing a solar panel system for their home, business, or farm.  You can check out the website for the⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ top solar energy equipment installer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, Solar Harmonics, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Jamie also is the creator and panel expert of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Straight-Talk Solar Cast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, the world's first podcast focused on answering the questions faced by anyone considering going solar.Thanks for joining us this week! Want to subscribe to Local SEO in 10? ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Connect with us on iTunes and leave us a review.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Have a question about Local SEO? Chances are we've covered it! Go to our ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠podcast website and check out our search feature⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.

"We proposed a concept to the American Society of Clinical Oncology (ASCO), recognizing that extravasation management requires significant interdisciplinary collaboration and rapid action. There can occasionally be uncertainty or lack of clear guidance when an extravasation event occurs, and our objective was to look at this evidence with the expert panel to create a resource to support oncology teams overall. We hope that the guideline can help mitigate harm and improve patient outcomes," Caroline Clark, MSN, APRN, AGCNS-BC, OCN®, EBP-C, director of guidelines and quality at ONS, told Chelsea Backler, MSN, APRN, AGCNS-BC, AOCNS®, VA-BC, oncology clinical specialist at ONS, during a conversation about the ONS/ASCO Guideline on the Management of Antineoplastic Extravasation. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 2, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the management of antineoplastic extravasation. Episode Notes  Complete this evaluation for free NCPD. ONS/ASCO Guideline on the Management of Antineoplastic Extravasation ONS Podcast™ episodes: Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 335: Ultrasound-Guided IV Placement in the Oncology Setting Episode 145: Administer Taxane Chemotherapies With Confidence Episode 127: Reduce and Manage Extravasations When Administering Cancer Treatments ONS Voice articles: Access Devices and Central Lines: New Evidence and Innovations Are Changing Practice, but Individual Patient Needs Always Come First New Extravasation Guidelines Provide Recommendations for Protecting Patients and Standardizing Care Standardizing Venous Access Assessment and Validating Safe Chemo Administration Drastically Lowers Rates of Adverse Venous Events This Organization's Program Trains Non-Oncology Nurses to Deliver Antineoplastic Agents Safely ONS books: Access Device Guidelines: Recommendations for Nursing Practice and Education (fourth edition) Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) ONS courses: Complications of Vascular Access Devices (VAD) and IV Therapy ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ ONS Oncology Treatment Modalities Clinical Journal of Oncology Nursing articles: Chemotherapy Extravasation: Incidence of and Factors Associated With Events in a Community Cancer Center Standardized Venous Access Assessment and Safe Chemotherapy Administration to Reduce Adverse Venous Events Oncology Nursing Forum article: Management of Extravasation of Antineoplastic Agents in Patients Undergoing Treatment for Cancer: A Systematic Review ONS huddle cards: Antineoplastic Administration Chemotherapy Immunotherapy Implanted Venous Port ONS position statements: Administration (Infusion and Injection) of Antineoplastic Therapies in the Home Education of the Nurse Who Administers and Cares for the Individual Receiving Antineoplastic Therapies ONS Guidelines™ for Extravasation Management ONS Oncologic Emergencies Learning Library ONS/ASCO Algorithm on the Management of Antineoplastic Extravasation of Vesicant or Irritant With Vesicant Properties in Adults American Society of Clinical Oncology (ASCO) Podcast: Management of Antineoplastic Extravasation: ONS-ASCO Guideline To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "The focus of this guideline was specifically on intravenous antineoplastic extravasation or when a vesicant or an irritant with vesicant properties leaks out of the vascular space. This can cause an injury to the patient that's influenced by several factors including the specific drug that was involved in the extravasation, whether it was DNA binding, how much extravasated, the affected area, and individual patient characteristics." TS 1:48 "The panel identified and ranked outcomes that mattered most with extravasation. Not surprising, one of the first was tissue necrosis. Like, 'How are we going to prevent tissue necrosis and preserve tissue?' The next were pain, quality of life, delays in cancer treatment: How is an extravasation going to delay cancer treatment that's vital to the patient? Is an extravasation also going to result in hospitalization or additional surgical interventions that would be burdensome to the patient? ... We had a systematic review team that then went in and summarized the data, and the panel applied the grading of recommendations, assessment, development, and evaluation (GRADE) criteria, grading quality of evidence and weighing factors like patient preferences, cost, and feasibility of an intervention. From there, they developed their recommendations." TS 7:35 "The panel, from the onset, wanted to make sure we had something visual for our readers to reference. They combined evidence from the systematic review, other scholarly sources, and their real-world clinical experience to make this one-page supplementary algorithm. They wanted it to be comprehensive and easy to follow, and they included not only those acute management steps but also guidance on 'How do I document this and what are the objective and subjective assessment factors to look at? What am I going to tell the patient?' In practice, for use of that, I would compare it to your current processes and identify any gaps to inform policies in your individual organizations." TS 16:34 "The guidelines don't take place of clinician expertise; they're not intended to cover every situation, but a situation that keeps coming up that we should talk about as a limitation, is we're seeing these case reports of tissue injury with antibody–drug conjugate extravasation. There's still not enough evidence to inform care around the use of antidotes with those agents, so this still needs to be addressed on a case-by-case basis. We still need publication of those case studies, what was done, and outcomes to help inform direction." TS 19:24 "Beyond the acute management is to ensure thorough documentation regarding extravasation. Whether you're on electronic documentation or on paper, are the prompts there for the nurse to capture all of the factors that should be captured regarding that extravasation? The size, the measurement, the patient's complaints. Is there redness? Things like that. And then within the teams, everyone should know where to find that initial extravasation assessment so that later on, if they're in a different clinic, they have something to go by to see how the extravasation is healing or progressing. ... I think there's an importance here, too, to our novice oncology nurses and their preceptors. This could be anxiety-provoking for the whole team and the patient, so we want to increase confidence in management. So, I think using these resources for onboarding novice oncology nurses is important." TS 22:34

Mia Horowitz, PhD, Tel Aviv University; Aitor Aguirre, PhD, Michigan State University, Michigan, USA; and Ying Sun, PhD, University of Cincinnati, discuss the use of organoid models in lysosomal disorder research and drug development.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, visit https://checkrare.com/learning/p-grids2025-session3-organoids-and-lab-grown-models-in-lysosomal-disorders/Learning ObjectivesDescribe the use of heart organoid models to better understand the pathophysiology of lysosomal disorders and its clinical relevanceDescribe the use and application of brain organoid models in neuropathic Gaucher disease research and treatmentFacultyMia Horowitz, PhD, Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University.Aitor Aguirre, PhD, Associate Professor of Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Chief, Division of Developmental and Stem Cell Biology (IQ), Director, MSU Stem Cell Core, Michigan State University.Ying Sun, PhD, Professor, Cincinnati Children's Hospital Medical Center, University of Cincinnati.DisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Mia Horowitz, PhDDr. Horowitz has no relevant financial relationships to disclose.Aitor Aguirre, PhDDr. Aguirre has no relevant financial relationships to disclose.Ying Sun, PhDDr. Sun receives research support from Enkefalos Biosciences and Yuhan Corporation.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

Behzad Najafian, MD, Professor, Department of Laboratory Medicine & Pathology, Department of Medicine at the University of Washington, Washington, USA discusses the use of artificial intelligence in identifying and managing lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, visit https://checkrare.com/learning/p-grids2025-session1-ai-in-medicine-transforming-the-landscape-of-tissue-based-diagnostics/Learning ObjectivesDescribe recent advances in the applications of AI in lysosomal disorder diagnosis and its clinical relevanceFacultyBehzad Najafian, MD Professor, Department of Laboratory Medicine & Pathology, Department of Medicine, University of WashingtonDisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Behzad Najafian, MDDr. Najafian is on the Advisory Board/Consultant for Sanofi, Amicus, Avrobio, 4DMT,Sangamo, Freeline, AceLink, Relay, CRISPR, ELOXX, SPARK, UNIQURE. He receives grants/research support from Amicus. Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

Stephan Stern, PhD, DABT, Director of Research and Development, Nanotechnology Characterization Lab (NCL), Frederick National Laboratory for Cancer Research, Maryland, USA; and Ruben Boado, PhD, Professor of Medicine, University of California at Los Angeles, California, USA, discuss the use of nanotechnology in the treatment of lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, visit https://checkrare.com/learning/p-grids2025-session2-nanotechnology-and-lysosomal-disorders/Learning ObjectivesDescribe recent advances in the use of nanotechnology to treat lysosomal disordersDescribe the role of nanotechnology in addressing unmet needs in lysosomal disordersFacultyStephan Stern, PhD, DABTDirector of Research and Development, Nanotechnology Characterization Lab (NCL), Frederick National Laboratory for Cancer ResearchRuben Boado, PhDProfessor of Medicine, University of California at Los AngelesDisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Stephan Stern, PhD, DABTDr. Stern has no relevant financial relationships to disclose. Ruben Boado, PhDDr. Boado has no relevant financial relationships to disclose.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

Oral Alpan, MD, Immunologist, Amerimmune, Virginia, USA; Svenja Keller, PhD student, University of Zurich, Switzerland; Shoshana Revel-Vilk, MD, PhD, Director, Gaucher Unit & Pediatric Hematology/Oncology Unit, Shaare Zedek Medical Center, Jerusalem, Israel; Patrick Deegan, MD, Consultant Metabolic Physician, University of Cambridge, UK; and Ravi Kamath, MD, PhD, Head of Musculoskeletal Radiology, Inova Health System, Virginia, USA, discuss the applications of AI in the diagnosis and treatment of lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, visit https://checkrare.com/learning/p-grids2025-session4-expanded-applications-of-ai-in-lysosomal-disorders/Learning ObjectivesDescribe how emerging AI and machine learning technologies are advancing disease modeling and biomarker development.Describe how emerging AI and machine learning technologies are advancing therapeutic target identification across lysosomal disorders.FacultyOral Alpan, MD, Immunologist, AmerimmuneSvenja Keller, PhD student, University of ZurichShoshana Revel-Vilk, MD, PhD, Director, Gaucher Unit & Pediatric Hematology/Oncology Unit, Shaare Zedek Medical CenterPatrick Deegan, MD, Consultant Metabolic Physician, University of CambridgeRavi Kamath, MD, PhD, Head of Musculoskeletal Radiology, Inova Health SystemDisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Oral Alpan, MD Dr. Alpan has no relevant financial relationships to disclose.Svenja KellerMs. Keller has no relevant financial relationships to disclose.Shoshana Revel-Vilk, MD, PhDDr. Revel-Vilk receives grant/research support from Sanofi and Takeda. She is a member of the Speakers Bureau for Sanofi and Takeda, and a member of the Advisory Board for Takeda.Patrick Deegan, MDDr. Deegan is a consultant and advisory board member with Sanofi, Takeda, and Amicus.He also receives research support from Sanofi and Amicus.Ravi Kamath, MD, PhDDr. Kamath is on an advisory board for Intrinsic Therapeutics. He is also a consultant forSanofi, Takeda, and Spur Therapeutics.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

Duarte C. Barral, PhD, Associate Professor, NOVA Medical School, NOVA University of Lisbon, Portugal; Nuno Raimundo, PhD, Associate Professor, Department of Cellular and Molecular Physiology; Penn State College of Medicine, Pennsylvania, USA; Betul Celik, PhD, Postdoctoral Fellow, Nemours Children's Health, Delaware, USA; and Gregory Newby, PhD, Assistant Professor, Department of Genetic Medicine, Johns Hopkins School of Medicine, Maryland, USA,discuss the principles of theranostics and its application in lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, please visit https://checkrare.com/learning/p-grids2025-session5-theranostics-and-lysosomal-disorders/ Learning ObjectivesDescribe lysosomal and inter-organelle mechanisms that contribute to pathology in lysosomal disorders, and how these pathways are being leveraged for diagnostic and therapeutic applications.Describe current and emerging theranostic strategies for lysosomal disorders.FacultyDuarte C. Barral, PhD, Associate Professor, NOVA Medical School, NOVA University of Lisbon, Nuno Raimundo, PhD, Associate Professor, Department of Cellular and Molecular Physiology; Penn State College of MedicineBetul Celik, PhD, Postdoctoral Fellow, Nemours Children's HealthGregory Newby, PhD, Assistant Professor, Department of Genetic Medicine, Johns Hopkins School of MedicineDisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Duarte C. Barral, PhD Dr. Barral's group receives grant support from Sea4Us.Nuno Raimundo, PhDDr. Raimundo has no relevant financial relationships to disclose.Betul Celik, PhDDr. Celik has no relevant financial relationships to disclose.Gregory Newby, PhDDr. Newby has no relevant financial relationships to disclose.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

Shunji Tomatsu, MD, PhD, Professor and Head, Nemours Children's Health, Delaware, USA; Alessandra d'Azzo, PhD, Emerita Faculty, Genetics, St. Jude Children's Research Hospital, Tennessee, USA; Merve Emecen Sanli, MD, Associate Professor, Department of Pediatrics, University of Texas Southwestern Medical Center, Texas, USA; and Ryan Colburn, patient with Pompe disease and president of Odimm Inc, discuss new and emerging gene therapies for lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, please visit https://checkrare.com/learning/p-grids2025-session6-current-issues-in-gene-therapies-for-lysosomal-disorders/  Learning ObjectivesDescribe current and emerging gene therapy data in lysosomal disorders and its clinical relevanceDescribe role of patients in gene therapy developmentFacultyShunji Tomatsu, MD, PhD, Professor and Head, Nemours Children's HealthAlessandra d'Azzo, PhD, Emerita Faculty, Genetics, St. Jude Children's Research HospitalMerve Emecen Sanli, MD, Associate Professor, Department of Pediatrics, University of Texas Southwestern Medical CenterRyan Colburn. Odimm, Inc.DisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Shunji Tomatsu, MD, PhD Dr. Tomatsu has received the following grants: Morquio Foundations and families: Scarlett Grifith, Bennett, A Cure for Roberts, and Morquio Conference; MPS Societies: Japanese, National, and Austrian; NIH grants: 1-R01-HD102545, NIH, NICHD, Tomatsu (PI), 1R01HD104814-01A1, NIH, NICHD, Langan, T.J. (PI), Role: Site-PI, R43HD114328-01, NIH, ACOSTA, WALTER (PI), Role: site PI, 1R43AR084638-01, NIH, MOUNZIH, KHALID (PI); Foundation of NIH: FNIH RFP NUMBER: 2022-BGTC-005 Tomatsu (PI). Alessandra d'Azzo, PhDDr. D'Azzo has no relevant financial relationships to disclose.Merve Emecen Sanli, MDDr. Sanli has no relevant financial relationships to disclose.Ryan ColburnMr. Colburn has an advisory, consulting and/or project based relationship or stock holding with: Abeona Therapeutics, Amicus Therapeutics, Astellas Gene Therapies, Avidity Biosciences, Bayer, Catalyst Pharmaceuticals, Denali Therapeutics, M6P Therapeutics, Sangamo Therapeutics, Sanofi, Solid Biosciences.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

"They [monoclonal antibodies] are able to cause tumor cell death by binding to and blocking to necessary growth factor signaling pathways for tumor cell survival. That's going to be dependent on the target of the antibody, but I'll give an example of epidermal growth factor, or EGFR. This is overexpressed in several different kinds of cancers where activation of this growth factor increases the amount of proliferation and migration of cancer cells. So, if we bind to it and block to it, then that would help halt these pathways and stop cancer cell growth," Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about monoclonal antibodies. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) (including 45 minutes of pharmacotherapeutic content) by listening to the full recording and completing an evaluation at courses.ons.org by December 26, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of monoclonal antibodies in the treatment of cancer.  Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 383: Pharmacology 101: Bispecific Antibodies Episode 375: Pharmacology 101: VEGF Inhibitors Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse's Role Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors ONS Voice articles: An Oncology Nursing Overview of Biosimilars Make Subcutaneous Administration More Comfortable for Your Patients Oncology Nurses' Role in Translating Biomarker Testing Results Reduce Chair Time by as Much as 16 Minutes by Priming IVs With Drug Shorter Administration Times Still Require High-Acuity Care The Names of Targeted Therapies Give Clues to How They Work ONS Voice drug reference sheets: Datopotamab deruxtecan-dlnk Enfortumab vedotin Margetuximab-cmkb Mirvetuximab soravtansine-gynx Nivolumab and hyaluronidase-nvhy Nivolumab and relatlimab-rmbw Pembrolizumab and berahyaluronidase alfa-pmph Retifanlimab-dlwr ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial Management of Immunotherapy Infusion Reactions Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma Oncology Nursing Forum articles: Administration of Subcutaneous Monoclonal Antibodies in Patients With Cancer Depressive Symptoms and Quality of Life Associated With the Use of Monoclonal Antibodies in Breast Cancer Treatment ONS huddle cards: Bispecifics Checkpoint Inhibitors Monoclonal Antibodies Other ONS resources: Biomarker Database Bispecific Antibodies video Patient Education Sheets Antibodies article: A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy Cureus article:  A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach Association of Cancer Care Centers (ACCC) homepage Cancer Immunology, Immunotherapy article: Therapeutic Antibodies in Oncology: An Immunopharmacological Overview Drugs@FDA package inserts Future Oncology article: Biosimilars: What the Oncologist Should Know Hematology/Oncology Pharmacy Association homepage National Comprehensive Cancer Network homepage Network for Collaborative Oncology Development and Advancement (NCODA) subcutaneous therapy article Oncolink: Side Effects of Immunotherapy World Health Organization: New International Nonproprietary Names (INN) Monoclonal Antibody Nomenclature Scheme To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Prior to monoclonal antibodies, all we really had were these toxic chemotherapies or toxic radiation, so it was recognized how great it would be if we could have a treatment that was much more specific to the tumor cells and have agents that have less toxicities. These advancements in monoclonal antibody production began in the 1980s. ... Eventually, we had the first monoclonal antibody that was approved by the U.S. Food and Drug Administration (FDA) for an oncologic indication, rituximab." TS 4:14  "Nowadays, we do have treatments that are also considered tumor-agnostic. This is when a patient has a certain biomarker, then that treatment can be given and FDA approval was given, regardless what type of tumor the patient has. We typically see these kinds of tumor-agnostic therapies more so in patients who have recurrent or advanced diseases in solid tumors. One monoclonal antibody example that comes to mind is dostarlimab. That's a checkpoint inhibitor that's approved for patients who are deficient in mismatch repair mechanism." TS 23:48 "Our immune system constantly has this surveillance system and it's able to recognize foreign pathogens, abnormal cells, and even precancerous cells. And they're able to eliminate them before they become cancerous. But on the flip side, one of the regulatory mechanisms that we have so our immune system doesn't attack itself is the presence of checkpoints. When these checkpoints bind to their ligands, this can then act as an off switch so that, again, our immune system is not going to attack itself. But then the tumor cells can take advantage of this and actually use this mechanism to evade the immune system. So, when we're giving a checkpoint inhibitor, now we're removing that off switch. As a consequence, common adverse effects can include things like immune mediated adverse events. These most commonly affect the skin, gastrointestinal tract, and liver. Essentially, this can cause any '-itis' you can think of." TS 26:36 "Looking at strategies to prevent infusion reactions, one example is the use of premedication. If premedication is recommended, this typically includes any combination of antipyretics, which is typically acetaminophen. Antihistamine, which is typically an H1 antagonist like diphenhydramine. Although, there could be cases where we want to substitute this agent because maybe the patient has been tolerating therapy okay, and they're having a lot of side effects. So, we might use a second-generation antihistamine in some cases. The premedication may be given with or without some kind of steroid, whether that's methylprednisolone, hydrocortisone, or dexamethasone." TS 29:53 "We tend to think of monoclonal antibody usage to be primary oncology, but that's not really the case. The first monoclonal antibodies that were developed were not for oncologic indications, they were for transplant indication for cardiac indication. So, they're really diversely utilized across all specialties and medicines. We have monoclonal antibodies for hyperlipidemia, for neurology, for rheumatology, so the uses are so very expansive across all specialties." TS 41:01

This roundtable conversation with leaders from the International Union of Painters and Allied Trades (IUPAT) explores the vital role of certifications in industrial painting, as well as areas in which a trained and certified workforce can boost the coatings industry. Topics include modern project requirements, certifications, and the industry's future; QP contractor requirements; how contractor accreditation can help ensure quality and protect investments; and the IUPAT's important role in raising the bar for industry standards.

In this episode of the ASC Podcast with John Goehle we discuss the current state of ASC Accreditation and the value of Accreditation and in our focus segment, Interview Tom Terranova with QuadA.   This episode is sponsored by Surgical Information Systems, RFX Solutions, Medserve and  Ambulatory Healthcare Strategies.   Notes and Resources from this Episode: QuadA Website: https://www.quada.org/ INFORMATION ABOUT THE ASC PODCAST WITH JOHN GOEHLE ASC Central, a sister site to http://ascpodcast.com provides a link to all of our bootcamps, educational programs and membership programs! https://conferences.asc-central.com/ Join one of our Membership Programs! Our Patron Program: Patron Members of the ASC Podcast with John Goehle have access to ASC Central - an exclusive membership website that provides a one-stop  ASC Regulatory and Accreditation Compliance, Operations and Financial Management resource for busy Administrators, nurse managers and business office managers.  More information and Become Member The ASC-Central Premium Access Program A Premium Resource for Ambulatory Surgery Centers including access to bootcamps, education programs and private sessions More Information and Become a Premium Access Program Members Today! Important Resources for ASCs: Conditions for Coverage: https://www.ecfr.gov/cgi-bin/text-idx?c=ecfr&rgn=div5&view=text&node=42:3.0.1.1.3&idno=42#se42.3.416_150 Infection Control Survey Tool (Used by Surveyors for Infection Control) https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/som107_exhibit_351.pdf Updated Guidance for Ambulatory Surgical Centers - Appendix L of the State Operations Manual (SOM) https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/som107ap_l_ambulatory.pdf https://www.cms.gov/medicareprovider-enrollment-and-certificationsurveycertificationgeninfopolicy-and-memos-states-and/updated-guidance-ambulatory-surgical-centers-appendix-l-state-operations-manual-som Policy & Memos to States and Regions CMS Quality Safety & Oversight memoranda, guidance, clarifications and instructions to State Survey Agencies and CMS Regional Offices. https://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/SurveyCertificationGenInfo/Policy-and-Memos-to-States-and-Regions Other Resources from the ASC Podcast with John Goehle: Visit the ASC Podcast with John Goehle Website Books by John Goehle Get a copy of John's most popular book - The Survey Guide - A Guide to the CMS Conditions for Coverage & Interpretive Guidelines for Ambulatory Surgery Centers 

Higher education enters 2026 under conditions that are no longer hypothetical. In this 8th annual end-of-year episode of the Changing Higher Ed® podcast, Dr. Drumm McNaughton is joined by Tom Netting of TEN Government Strategies to review how the predictions made at the end of 2024 played out during the 2025 operating year and what those outcomes mean for institutional planning in 2026. Rather than offering speculative forecasts, this episode uses 2025 as a calibration year. When predictions materialize, they remove ambiguity. They clarify which pressures are structural, which risks persist, and which leadership assumptions are no longer defensible. For presidents, boards, and senior leadership teams preparing for 2026, this conversation provides a grounded planning context based on conditions already in motion. Topics Covered What 2025 confirmed about federal policy instability, accountability, cost pressure, enrollment volatility, and governance risk Why the Department of Education is likely to remain in place through 2026 and why its continued existence should not be mistaken for stability How redistribution of authority across federal agencies increases compliance complexity for institutions Where student loans are likely to move within the federal system and why institutions face growing exposure to borrower outcomes Why broad student debt forgiveness remains unlikely and what limited relief options may realistically emerge How accountability is shifting toward program-level scrutiny and the implications for academic realignment Why accreditation reform remains unsettled and why leaders should treat accreditation as a strategic risk factor Workforce Pell expansion, quality oversight challenges, and the risk of fraud and abuse in short-term credentials The growing role of states in accountability as federal capacity contracts Research funding as political leverage and the planning risk created by funding uncertainty Polarization as an operational challenge affecting enrollment, safety, governance, and public trust Technology, AI, cybersecurity, and NIST compliance as board-level responsibilities Enrollment, demographic decline, cost escalation, and financial pressure entering the 2026 planning cycle Mergers, closures, and structural collaboration as necessary adaptation strategies Key Planning Judgments for 2026 The Department of Education will persist but continue to shrink and fragment Student loans will move further away from the Department, increasing institutional exposure Accountability pressure will intensify, particularly at the program level Accreditation reform will remain unresolved beyond 2026 Workforce Pell will expand, bringing both opportunity and heightened oversight risk Research funding will remain politically vulnerable Cost pressure will continue to drive consolidation and closures Technology and cybersecurity will demand sustained leadership attention This episode is especially relevant for presidents and trustees navigating compressed decision timelines, thinner margins for error, and declining tolerance for ambiguity. The focus is not prediction for its own sake, but clarity about the forces institutions must plan around as they enter 2026. #HigherEducation #HigherEd2026StrategicPlanning #HigherEducationPodcast

India's top human rights body, the National Human Rights Commission (NHRC), is going to have its accreditation status downgraded -- from ‘A' to ‘B'. The Global Alliance of National Human Rights Institutions (GANHRI) is the international body that mediates the relationship between national human rights institutions and the United Nations (UN).  In March this year, GANHRI's Sub-Committee on Accreditation recommended that India's accreditation status be downgraded to ‘B'. India appealed this move to the GANHRI bureau. Earlier this month, the appeal was turned down. This means that from April 2026, India's NHRC will no longer enjoy the ‘A' category accreditation that it has enjoyed till now – a major embarrassment for the institution, and also for India.  What were the reasons for this downgrading? Why was our appeal turned down? What can India do to get the ‘A' accreditation back?  Guest: Henri Tiphagne, Working Secretary with the All India Network of Individuals and Organisations working with National and State Human Rights Institutions (AINNI). Host: G. Sampath Edited by Sharmada Venkatasubramanian Learn more about your ad choices. Visit megaphone.fm/adchoices

"The thought of recurrence is also a psychosocial issue for our patients. They're being monitored very closely for five years, so there's always that thought in the back of their head, 'What if the cancer comes back? What are the next steps? What am I going to do next?' It's really important that we have conversations with patients and their families about where they're at, what we're looking for, and reassure them that we'll be with them during this journey and help them through whatever next steps happen," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer survivorship considerations for nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by December 19, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to survivorship nursing considerations for people with prostate cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 390: Prostate Cancer Treatment Considerations for Nurses Episode 387: Prostate Cancer Screening, Early Detection, and Disparities Episode 201: Which Survivorship Care Model Is Right for Your Patient? Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: APRNs Collaborate With PCPs on Shared Survivorship Care Models Exercise Before ADT Treatment Reduces Rate of Side Effects Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer Here Are the Current Nutrition and Physical Activity Recommendations for Cancer Survivors Nursing Considerations for Prostate Cancer Survivorship Care Regular Physical Activity and Healthy Diet Lower Risk of All-Cause and Cardiac Mortality in Prostate Cancer Survivors Sexual Considerations for Patients With Cancer Sleep Disturbance Is Part of a Behavioral Symptom Cluster in Prostate Cancer Survivors ONS course: Essentials in Survivorship Care for the Advanced Practice Provider Clinical Journal of Oncology Nursing articles: A Patient-Specific, Goal-Oriented Exercise Algorithm for Men Receiving Androgen Deprivation Therapy Incorporating Nurse Navigation to Improve Cancer Survivorship Care Plan Delivery Prostate Cancer: Survivorship Care Case Study, Care Plan, and Commentaries The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population Oncology Nursing Forum articles: A Qualitative Exploration of Prostate Cancer Survivors Experiencing Psychological Distress: Loss of Self, Function, Connection, and Control Identification of Symptom Profiles in Prostate Cancer Survivors Sleep Hygiene Education, ReadiWatch™ Actigraphy, and Telehealth Cognitive Behavioral Training for Insomnia for People With Prostate Cancer Understanding Men's Experiences With Prostate Cancer Stigma: A Qualitative Study Other ONS resources: Late Effects of Cancer Treatment Huddle Card Survivorship Care Plan Huddle Card Survivorship Learning Library American Cancer Society (ACS): Living as a Prostate Cancer Survivor ACS prostate cancer survivorship studies To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Some of the most common late side effects [are] urinary, bowel, and sexual dysfunction issues. For urinary effects, it can include urgency and frequency, some incontinence, or a weak or slow urine stream that frequently bothers the patient after treatment. Bowel effects can happen such as constipation, diarrhea, or inflammation of the rectum, which can lead to bleeding or mucus discharge. And then erectile dysfunction is another side effect that patients with prostate cancer often deal with and have to work with their physicians on, depending on what they want with that function. Fatigue, lymphedema, and skin changes can also occur after treatment." TS 1:40 "If we can catch [prostate cancer] and take care of it at an early stage, overall survival is about 90%. If the disease is localized, it's 99%. If we can take out the prostate, radiate the prostate, we can do something with that—localized, 99% survival rate. If there's regional metastasis, it's about 90%. And if there's distant metastasis, it's about 30% survival." TS 3:55 "Prostate cancer recurs in about 20%–30% of patients within the first five years of initial treatment. ... There's not a lot of research out there that shows what can reduce risk, but what has been shown to be effective is regular exercise, quitting smoking, and eating a healthy diet. ... It's really important for our patients to understand the importance of having follow-up visits so that we can catch a recurrence quickly instead of waiting years down the road. Prostate cancer is usually a slow-growing disease, so if we can pick it up quickly in those revisits, we can start another treatment for the patient." TS 6:00 "Sexuality is not something many people are comfortable discussing, but we really need to talk with patients and let them know that this is normal. It is normal that you may have some sexual dysfunction. It's normal that you may not feel the way you did before. Talk to us about it, let us know where you're at, let us know what your goals are, because there are a lot of things we can do. There are medications we can use for impedance. There are devices and implants available to help the patient to support them and give them whatever their goal is for their sexuality." TS 9:41 "Providing survivorship care plans are important for these patients—something that can be sent off to everyone else that's caring for that patient. You have your primary care physician, urologist, oncologist, the oncology nurse, maybe a navigator, and [others] who are looking into this patient. So, giving that patient a survivor care plan and putting it with their files to include a summary of the treatment received, because most of the time a patient is not going to remember exactly what they received. A suggested schedule for follow-up exams—so again, if a primary care provider is not used to dealing with a patient with prostate cancer, they have something to go off of. A schedule of other tests they may need in the future including screening for other types of cancer. Are they a smoker? Do they need lung screening? Do they need any other screenings related to types of cancers? And then a list of possible late or long-term side effects." TS 15:16 "I think a lot of people know about the long-term sexual effects, but what we don't really talk about is the effect that it has on the patient's self-image. How they define themselves, how they look, their body image, their self-image. It's really important that we continue to discuss it with patients and make them comfortable when discussing their sexuality and their goals for sexuality. They may be having these self-image issues after treatment that they're just not telling us about and that can affect their quality of life." TS 18:38

 Join us as Diana Diaz, Executive Director of the Brain Injury Network (BIN), walks us through BIN's 2025 successes and challenges. Starting with earning a 3-year accreditation from the Commission on Accreditation of Rehabilitation Facilities (CARF), to elevating our interns and volunteers, to celebrating bindwaves' achievements, to adapting to changing fundraising needs, and finally to launching a Mobile Clubhouse that reimagines what a traditional clubhouse can be. Diana shares how BIN continues to grow and strengthen the brain injury community. The message of hope she wants to share is “when you come to BIN as a member, we'll find a way to challenge you at your level.” This message is so powerful and uplifting for brain injury survivors because we know there is a haven for us to learn, grow, and acclimate back into life.Social Media www.thebind.orghttps://www.facebook.com/thebindorghttps://www.instagram.com/thebindorg/Send us a textSupport the showYou can find this episode's transcript here.New episodes drop every other Thursday everywhere you listen to podcasts.

In this episode of the Mad Rush Podcast, host Trisha Addicks is joined by her long-time friend and accomplished entrepreneur, Sarah Alvarez. They discuss essential business advice, such as focusing on what your business needs rather than what you're best at and hiring the right people. Sarah shares her journey through launching a toy company, working with Cristo Rey Atlanta Jesuit High School, and managing Wax Pot wax studios. They share key lessons from their careers and emphasize the importance of having an exit strategy and persevering through hardships. They also underscore the value of giving individuals agency and recognizing the role of opportunity in success. This episode features impactful stories and valuable insights for aspiring entrepreneurs and anyone interested in personal growth.

In this heartfelt episode of Fly to Freedom, I have the privilege of speaking with Di Archer, the CEO and co-founder of tastelife UK. Di shares her personal journey into the world of eating disorders, detailing how her family's experience led to the creation of tastelife UK—a charity dedicated to providing support, education, and recovery tools for those affected by eating disorders. We delve into the challenges faced by families, the importance of understanding eating disorders beyond the surface, and the transformative power of community support in the recovery process.Key Takeaways:Personal Journey: Di discusses her family's initial lack of understanding about eating disorders and how a personal crisis led to the founding of tastelife UK.Founding of tastelife UK: Established in 2014, tastelife UK offers an 8-session Community Recovery Course designed for individuals and families affected by eating disorders. Community Support: The charity emphasizes the importance of community in recovery, providing a safe space for individuals and families to share experiences and support each other.Prevention and Education: Tastelife UK focuses on prevention by offering resources for young people in schools and youth groups, aiming to equip them with the knowledge to avoid developing eating disorders. Recovery Tools: The Community Recovery Course is non-threatening, educational, and encourages a self-help approach, helping individuals and families break free from eating disorders.Accreditation and Training: Tastelife UK provides accredited training for leaders to run recovery courses, ensuring quality support for those affected. Listen to the full episode here:About Di Archer:Di is a trainer, writer, and speaker with a theological background. Family experience led to her co-founding and now heading up tastelife. She loves working with the gifted tastelife team and volunteers, and is delighted that together they offer such innovative and effective resources for those affected by eating disorders. Di and her husband Graham have three grown-up children, an assortment of gorgeous grandchildren... and a hot tub. The latter for medicinal purposes, of course! (tastelifeuk.org)Connect with Di Archer and tastelife UK:Website: (tastelifeuk.org)Email: di.archer@tastelifeuk.orgSocial Media:Facebook: tastelife UKTwitter: @tastelifeukInstagram: @tastelifeuk

Let's be honest,  public school wasn't designed for kids with ADHD. Too often, these kids are labeled, misunderstood, and pushed into systems that don't fit how their brains learn best. But what if the problem isn't your child, but the system itself? In this episode of The Soaring Child Podcast, host Dana Kay, ADHD health practitioner and founder of the ADHD Thrive Method for Kids speaks with Leslie Dernberger, founder of Aspire Education, mom of four, and one of the nation's leading experts in K–12 education for neurodiverse learners. Drawing on her legal background and over a decade of experience helping families, Leslie unpacks why traditional schooling often fails ADHD kids and what parents can do about it. From understanding homeschool laws and navigating deschooling, to structuring the day and busting common misconceptions, this episode is filled with practical guidance and encouragement. Whether you're curious about homeschooling, exploring hybrid options, or just want to better support your child's learning, this conversation will give you hope and actionable tools. Links Mentioned in the Show:▶ Aspire Education: https://www.aspireeducation.us/ ▶ Homeschool Legal Defense Association (HSLDA): https://hslda.org Key Takeaways: [00:00] Public school isn't built for many ADHD learners andwhy fit-the-mold systems backfire. [02:37] Meet Leslie Dirnberger (Aspire Education): mom of four, homeschool veteran, legal background, supports thousands of families. [04:23] The "catalyst event": what finally pushes parents to seek alternatives. [06:03] Spotting the signal: "the spark is gone" and nothing at school is fixing it. [07:16] First steps legally: understand your state's rules; public vs. private education; where homeschooling fits. [10:05] Deschooling 101: reset the parent first; museum/nature learning to reconnect. [13:38] Foundation step: define "a good education" as a family; ask kids what learning should look like. [15:24] Myth-busting socialization: why homeschoolers often get better real-world social practice. [18:30] Colleges love homeschoolers: time management, self-advocacy, executive function. [26:27] Standardized tests miss the mark, especially for ADHD,  focus on mastery instead. Memorable Moments: "The truth is, your child doesn't need to be fixed. They need an education that actually fits their brain." "There is a catalyst event that has occurred that creates a situation that the parents go, wait a second, let's take a step back here." "The spark has gone out, the light has gone out of their eyes and the parents know something's wrong." "The hardest part of homeschooling? Looking myself in the mirror and challenging my own beliefs." "What does a good education look like for your family and for your children?" "Nothing could be further from the truth — homeschoolers are often better socialized." "Colleges love homeschoolers because they know how to manage their time and advocate for themselves." "Accreditation is a game. It is absolutely garbage. It doesn't mean a thing." "Everything is geared towards standardized testing in government schools. And that's why they're in a box and they ram it through, which is terrible for ADHD kids." "Your children can own their own education and advocate for themselves at school." Dana Kay Resources:

In this episode, Dr. Tracy Baynes, founder and CEO of STEP (Student Expedition Program), shares her journey from oceanography to education, focusing on empowering low-income high school students in Arizona. She discusses the challenges these students face, the importance of family support, and the transformative experiences provided by STEP. Dr. Baynes emphasizes the significance of hard work, internal motivation, and creating generational change through education, while also inviting listeners to get involved with her nonprofit organization.CHAPTERS(00:00) Introduction to Dr. Tracy Baines and STEP(02:37) Connecting Oceanography to Education(05:51) The Launch of STEP and Its Mission(10:00) Comprehensive Support for Students(12:03) Challenges Faced by Students(15:38) The Role of Family Support(21:06) Overcoming Doubts and Building a Nonprofit(23:26) The Importance of Education and Lifelong Learning(28:25) Creating Generational Change Through Education(29:13) Getting Involved with STEPRESOURCES Dr. Tracy BaynesSTEP Expedition and College PrepInstagramCONNECT WITH ANDREA⁠Andreadelacerda.com⁠Get Your Business Audit⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. . .ABOUT ANDREA DE LA CERDAAndrea De La Cerda is a highly accomplished communications professional with over 25 years of experience in the fields of advertising, communications, and marketing. Throughout her career, Andrea has held key positions in renowned advertising agencies, brand consultancies and in-house marketing departments before creating Kandula. She possesses a deep understanding of consumer behavior and market trends, allowing her to develop innovative communication strategies that resonate with diverse audiences. Andrea received both her B.A. in Advertising and Business Administration and a M.A. in Education from Pepperdine, as well as her Accreditation in Public Relations and is a member of PRSA.. . .WORK WITH USKandula works with nonprofits, entrepreneurs, educational institutions, and established brands dedicated to expanding their influence and amplifying their impact through purpose-driven communication strategies. Reach out to work with us!

Ever worry about finding yourself in a civil or criminal case as a result of your actions as a nurse?  Join the co-hosts as they welcome Attorney Rachel Giles to help us demystify nursing legal liability, including must-dos, don't-dos, and real-world pitfalls so you can protect your license, your patients, and your peace of mind. (AMSN Members Earn 0.5 CE Hours*) * This episode is eligible for 0.5 contact hours for AMSN members who listen to the episode and submit a completed evaluation through the online library. None of the individuals with the ability to control the content of this episode have any relevant financial relationships with ineligible companies to disclose. The Academy of Medical Surgical Nurses is an accredited provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.   SPECIAL GUEST Rachel Giles, JD, MBA/MHA is a United States Army Veteran, brings over a decade of experience in health law, compliance, federal regulations, and risk management. She is dedicated to delivering innovative conflict resolution, consulting, education, and knowledge, leveraging her unique expertise to help clients and healthcare organizations navigate complex challenges in both legal and operational environments. Rachel is passionate about fostering effective communication and equitable solutions to ensure that every person feels safe and empowered to move forward confidently. Rachel's professional experience includes serving as CEO of Giles Mediation, LLC., where she assist low socioeconomic status clients mediate cases in an attempt to stay out of a long costly court battle. She was the Vice President of Compliance & Administration for AshtonBridge Capital, where she implemented risk management frameworks and compliance protocols across diverse industries such as investment, real estate, and commodity trading. Additionally, her tenure in senior roles at multiple Healthcare Organizations within the Texas Medical Center in Houston highlights her skill in mitigating risks, conducting audits, and driving quality and patient safety improvement initiatives. She is adept at contract negotiation, policy development, and litigation support, making her a trusted advisor to organizations. Academically, Rachel holds a Doctorate in Law with a specialization in Compliance, Regulatory Affairs, and Risk Management, alongside dual master's degrees in Business and Health Administration. Her credentials are complemented by certifications in Lean Six Sigma, Project Management, and Mediation. She was recognized for academic excellence, including achieving top marks in cybersecurity coursework, where she developed actionable strategies for addressing HIPAA data breaches. Her ability to merge research with practical application has been a hallmark of her professional and academic career.   MEET OUR CO-HOSTS Samantha Bayne, MSN, RN, CMSRN, NPD-BC is a nursing professional development practitioner in the inland northwest specializing in medical-surgical nursing. The first four years of her practice were spent bedside on a busy ortho/neuro unit where she found her passion for newly graduated RNs, interdisciplinary collaboration, and professional governance. Sam is an unwavering advocate for medical-surgical nursing as a specialty and enjoys helping nurses prepare for specialty certification.    Kellye' McRae, MSN-Ed, RN is a dedicated Med-Surg Staff Nurse and Unit Based Educator based in South Georgia, with 12 years of invaluable nursing experience. She is passionate about mentoring new nurses, sharing her clinical wisdom to empower the next generation of nurses. Kellye' excels in bedside teaching, blending hands-on training with compassionate patient care to ensure both nurses and patients thrive. Her commitment to education and excellence makes her a cornerstone of her healthcare team.   Marcela Salcedo, RN, BSN is a Floatpool nightshift nurse in the Chicagoland area, specializing in step-down and medical-surgical care. A member of AMSN and the Hektoen Nurses, she combines her passion for nursing with the healing power of the arts and humanities. As a mother of four, Marcela is reigniting her passion for nursing by embracing the chaos of caregiving, fostering personal growth, and building meaningful connections that inspire her work.   Eric Torres, ADN, RN, CMSRN is a California native that has always dreamed of seeing the World, and when that didn't work out, he set his sights on nursing.  Eric is beyond excited to be joining the AMSN podcast and having a chance to share his stories and experiences of being a bedside medical-surgical nurse.   Maritess M. Quinto, DNP, RN, NPD-BC, CMSRN is a clinical educator currently leading a team of educators who is passionately helping healthcare colleagues, especially newly graduate nurses. She was born and raised in the Philippines and immigrated to the United States with her family in Florida. Her family of seven (three girls and two boys with her husband who is also a Registered Nurse) loves to travel, especially to Disney World. She loves to share her experiences about parenting, travelling, and, of course, nursing!   Sydney Wall, RN, BSN, CMSRN has been a med surg nurse for 5 years. After graduating from the University of Rhode Island in 2019, Sydney commissioned into the Navy and began her nursing career working on a cardiac/telemetry unit in Bethesda, Maryland.  Currently she is stationed overseas, providing care for service members and their families.  During her free time, she enjoys martial arts and traveling. 

It's YOUR time to #EdUp with Dr. Maria Toyoda, President & CEO, WASC Senior College & University CommissionIn this episode, sponsored by the 2026 InsightsEDU Conference in Fort Lauderdale, Florida, February 17-19,YOUR host is Dr. Joe SallustioHow does a new CEO take the reins of an accreditation body serving 215 institutions & shift the narrative from compliance enforcers to champions of innovation & continuous quality improvement?What happens when accreditors focus on better data for better conversations & reject the misconception that they're just policemen instead of partners in advancing educational excellence?How does an accreditation leader navigate major disruptions in higher education through AI integration, short term Pell rollouts, & regulatory evolution while keeping students at the center of everything?Listen in to #EdUpThank YOU so much for tuning in. Join us on the next episode for YOUR time to EdUp!Connect with YOUR EdUp Team - ⁠⁠⁠⁠⁠ ⁠⁠⁠⁠Elvin Freytes⁠⁠⁠⁠⁠⁠⁠⁠⁠ & ⁠⁠⁠⁠⁠⁠⁠⁠⁠ Dr. Joe Sallustio⁠⁠⁠⁠● Join YOUR EdUp community at The EdUp ExperienceWe make education YOUR business!P.S. Want to get early, ad-free access & exclusive leadership content to help support the show? Then ⁠​subscribe today​⁠ to lock in YOUR $5.99/m lifetime supporters rate! This offer ends December 31, 2025!

Navigating Dementia – Related Behaviors Evaluation and Credit:  https://www.surveymonkey.com/r/medchat85   Target Audience             This activity is targeted toward primary care physicians and advanced providers.   Statement of Need  This podcast will address common behavioral and psychological symptoms (BPSD) associated w/ dementia and provide strategies for clinicians to recognize and manage. Up to 90% of individuals with dementia can suffer from BPSD that can include agitation, anxiety, depression, hallucinations and aggression This can be challenging for care givers, patients and care teams.   Objectives List common behavioral and psychological symptoms (BPSD) associated with dementia. Identify environmental, medical and psychosocial factors that can contribute to BPSD. Discuss evidence-based strategies to evaluate and manage BPSD, minimizing antipsychotics and highlighting non-pharmacological.  Moderator Greg E. Cooper, M.D., Ph.D. Chief, Adult Neurology Medical Director, Memory Center Norton Neuroscience Institute.   Speaker Rachel Hart, D.O. Geriatric Medicine Physician Memory and Cognitive Disorders Specialist Norton Neuroscience Institute Memory Center   Planner Disclosure   The planners of this activity do not have any relevant financial relationships with ineligible companies to disclose.   Moderator and Speaker Disclosure The speaker, Gregory Cooper, M.D., Ph.D., discloses relevant financial relationships with Eli Lilly and Eisai (research). The moderator, Rachel Hart, D.O., discloses a relevant financial relationship with Eli Lilly (faculty).   All relevant financial relationships have been successfully mitigated.   Commercial Support   There was no commercial support for this activity.    Physician Credits Accreditation  Norton Healthcare is accredited by the Kentucky Medical Association to provide continuing medical education for physicians.   Designation  Norton Healthcare designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.   Nursing Credits Norton Healthcare Institute for Education and Development is approved as a provider of nursing continuing professional development by the South Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. This continuing professional development activity has been approved for 0.50 ANCC CE contact hours. In order for nursing participants to obtain credits, they must claim attendance by attesting to the number of hours in attendance.     For more information related to nursing credits, contact Sally Sturgeon, DNP, RN, SANE-A, AFN-BC at (502) 446-5889 or sally.sturgeon@nortonhealthcare.org.   Social Worker Credits This activity will provide .50 hours of required continuing education units. National Association of Social Workers, Kentucky Chapter (NASW-KY) is an approved provider for social work credits through the Kentucky Board of Social Work. NASWKY#06/30/25.   For information about social worker credits, please send an email to cme@nortonhealthcare.org.   Resources for Additional Study/References Guideline Recommendations on Behavioral and Psychological Symptoms of Dementia: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/38640961/   Nonpharmacological Interventions for Management of Behavioral and Psychological Symptoms of Dementia in Long-Term Care Facilities by Direct Caregivers: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/35771069/   Date of Original Release | Dec. 2025; Information is current as of the time of recording.  Course Termination Date | Dec. 2027 Contact Information | Center for Continuing Medical Education; (502) 446-5955 or cme@nortonhealthcare.org   Also listen to Norton Healthcare's podcast Stronger After Stroke. This podcast, produced by the Norton Neuroscience Institute, discusses difficult topics, answers frequently asked questions and provides survivor stories that provide hope.   Norton Healthcare, a not for profit health care system, is a leader in serving adult and pediatric patients throughout Greater Louisville, Southern Indiana, the commonwealth of Kentucky and beyond. More information about Norton Healthcare is available at NortonHealthcare.com.

In this conversation, Dr. Eva Altobelli discusses the transformative potential of psychedelic therapy, addressing common misconceptions and emphasizing its benefits for personal and spiritual growth. The dialogue explores the unique challenges faced by women in managing mental health, societal expectations, and the importance of self-care. This conversation concludes with a focus on community support and the necessity of not navigating these journeys alone.. . . EPISODE CHAPTERS(00:00) Introduction to Psychedelic Therapy(03:54) Misconceptions and Benefits of Psychedelic Therapy(06:30) Understanding Client Experiences and Aspirations(11:26) The Role of Women in Mental Health and Self-Care(16:19) Transformational Therapies and Self-Discovery(21:14) Preparing for Psychedelic Therapy Sessions(24:50) Exploring the World of Psychedelics(26:35) The Therapeutic Benefits of Ketamine(29:23) Resilience and Mental Health for High-Achieving Women(31:57) Navigating Boundaries in Relationships(34:36) The Process of Integration in Healing(36:19) Practical Steps for Prioritizing Mental Health(38:57) The Evolution of Mental Health Practices(41:42) Community and Connection in Healing . . . RESOURCES Dr. Altobelli⁠⁠⁠⁠⁠Call or Text: 424-877-1333Get Your Business AuditInsight Timer CONNECT WITH ANDREAAndreadelacerda.comInstagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. . .ABOUT ANDREA DE LA CERDAAndrea De La Cerda is a highly accomplished communications professional with over 25 years of experience in the fields of advertising, communications, and marketing. Throughout her career, Andrea has held key positions in renowned advertising agencies, brand consultancies and in-house marketing departments before creating Kandula. She possesses a deep understanding of consumer behavior and market trends, allowing her to develop innovative communication strategies that resonate with diverse audiences. Andrea received both her B.A. in Advertising and Business Administration and a M.A. in Education from Pepperdine, as well as her Accreditation in Public Relations and is a member of PRSA.. . .WORK WITH USKandula works with nonprofits, entrepreneurs, educational institutions, and established brands dedicated to expanding their influence and amplifying their impact through purpose-driven communication strategies. Reach out to work with us!

Looking for daily inspiration?  Get a quote from the top leaders in the industry in your inbox every morning.   Every year, millions of attraction visitors lose hours in line instead of making memories. Since its inception, accesso's virtual queuing has saved more than 4.5 billion minutes of wait time, freeing guests to pack their day with more rides, eats, and excitement. The result? Happier guests who spend more and a better bottom line for you. Ready to turn waits into wins? Visit accesso.com/ROIClinic. The queues are virtual. The results are real. Salma Abassaly is the co-founder and managing partner of CERTIS LLC. Born and raised in Paris, she moved to the United Arab Emirates in 2007 and built a career that spanned luxury hospitality, corporate services, managing children's play areas, and leading leisure facilities before becoming an entrepreneur. CERTIS LLC is a UAE-based inspection and certification body that serves rides, attractions, and leisure facilities, pairing technical rigor with real-world operational insight. In this interview, Salma talks about inspections and certifications, relationship capital, and normalizing diversity. Inspections and certifications “We work with leading operators regionally and we ensure their rides meet international standards and we offer them an end-to-end approach from concept design to installation inspection as well as their ongoing operational audits and inspection.” Salma explains that CERTIS LLC provides an end-to-end approach, from concept and installation inspections through ongoing operational audits and periodic inspections. Her own operator background means she “speaks the language of the operators,” helping clients see an inspection body not as a cost or constraint but as an ally that aligns perception and reality through standards. She and her partner, Fadi, intentionally balance operational fluency and technical rigor so there is “no gap” when addressing client concerns. She also emphasizes credibility as foundational. Accreditation was the stamp that allowed CERTIS LLC to demonstrate quality, reliability, and transparency from day one, opening doors with regional leaders and setting a bar the company intends to uphold as it grows across the region and into emerging markets. Relationship capital “I think the transaction is the ultimate accomplishment of the relationship through the company, but before that, there's the relationship.” Relationships are not just a tactic for Salma; they are a metric of success. She prioritizes availability, consistency, and nurturing human connections beyond business, noting that trust built early makes hard conversations possible when inspections surface issues clients would rather not hear. To protect the partnership at the heart of CERTIS LLC, she and Fadi even engaged in proactive relationship coaching at the company's founding to set ground rules for how they would show up, disagree, and decide together. That investment sustains a culture of collaboration with each other and with clients, where long-term partnership matters as much as revenue. Salma adds that surrounding yourself with people who are “smarter than you” elevates outcomes and turns competition into collaboration. Growth, she says, is rarely linear; persistence, shared purpose, and strong partners win over time. Normalizing diversity “The goal is not really to highlight gender, but more to normalize diversity.” Reflecting on often being one of few women in boardrooms, Salma argues that representation fuels aspiration and that women's leadership brings emotional intelligence, resilience, and collaboration that benefit teams and guests alike. Her advice to women entering the industry is to lead as their authentic selves, not by copying stereotypically male behaviors. She hopes her daughter's generation won't even need to notice whether there are two women in a meeting, because diversity will simply be normal. Salma also shares her experience of the UAE as dynamic, opportunity-rich, and safe, with visible commitment to entrepreneurship and women in leadership. That environment, she says, has enabled her to turn vision into reality and to scale with clarity of purpose.   To connect with Salma directly, reach out to her on LinkedIn, and to learn more about the company, visit the CERTIS LLC website. This podcast wouldn't be possible without the incredible work of our faaaaaantastic team:   Scheduling and correspondence by Kristen Karaliunas   To connect with AttractionPros: AttractionPros.com AttractionPros@gmail.com AttractionPros on Facebook AttractionPros on LinkedIn AttractionPros on Instagram AttractionPros on Twitter (X)

Louisiana's surgeon general has been critical of vaccines. Now, Dr. Ralph Abraham has a new job as the second-in-command at the Centers for Disease Control and Prevention. WWNO and WRKF's Rosemary Westwood has spent the year reporting on Abraham's leadership at the Louisiana Department of Health. She joins us for more on his appointment and why some doctors have been critical. The once-mundane process of college accreditation has become political, ever since the Trump administration began targeting universities' diversity, equity and inclusion mandates. Now, six southern schools have formed their own accreditation agency rather than rely on the national model that has been around for decades. Reporter for Stateline Robbie Sequeira tells us more about the Trump administration's ongoing influence in higher education.__Today's episode of Louisiana Considered was hosted by Diane Mack. Our managing producer is Alana Schreiber, and our assistant producer is Aubry Procell. Our engineer is Garrett Pittman.You can listen to Louisiana Considered Monday through Friday at noon and 7 p.m. It's available on Spotify, the NPR App, and wherever you get your podcasts. Louisiana Considered wants to hear from you! Please fill out our pitch line to let us know what kinds of story ideas you have for our show. And while you're at it, fill out our listener survey! We want to keep bringing you the kinds of conversations you'd like to listen to.Louisiana Considered is made possible with support from our listeners. Thank you!

This conversation explores the multifaceted role of beauty schools in empowering students through guidance, resilience, and professional development. Beauty School Bobbi and Stephen Brown discuss the importance of providing life advice, navigating challenges, and creating a supportive learning environment. They emphasize the significance of accreditation and the need for students to find the right beauty school that aligns with their goals. Additionally, the conversation highlights the value of advanced education and the continuous improvement of educational practices to foster a thriving community in the beauty industry.   Takeaways The mission of beauty schools is to empower students. Providing life advice can have a lasting impact. It's important to equip students with problem-solving tools. Resilience is key in navigating life's challenges. Accreditation ensures quality education in beauty schools. Students should feel comfortable in their learning environment. Advanced education opens up more career opportunities. Creating a professional identity is crucial in the beauty industry. Continuous improvement is essential for educational success. Community engagement enhances the learning experience.   Chapters 00:00 Empowering Students Through Guidance 02:48 Navigating Challenges and Building Resilience 06:08 Creating a Supportive Learning Environment 08:56 The Importance of Accreditation in Beauty Schools 11:51 Finding the Right Beauty School 14:49 Advanced Education and Career Opportunities 18:08 Building a Professional Identity in the Beauty Industry 20:50 Continuous Improvement and Community Engagement   www.beautyschoolbobbi.com www.beautyandstylenetwork.com   Follow Beauty and Style Network: @beautystylenet Beauty School Bobbi: @beautyschoolbobbi Stephen Brown: @vicepresofbeauty Tennessee School of Beauty: @tnschoolofbeauty American Association for Career Schools: @aacschools

"Antibody–drug conjugates (ADCs) have three basic parts: the antibody part, the cytotoxic chemo, and the linker that connects the two. First, the antibody part binds to the target on the surface of the cell. Antibodies can be designed to bind to proteins with a very high level of specificity. That's what gives it the targeted portion. Then the whole thing gets taken up by the cell and broken down, which releases the chemotherapy part. Some sources will call this the 'payload' or the 'warhead.'  That's the part that's attached to the 'heat-seeking' part, and that's what causes the cell death," Kenneth Tham, PharmD, BCOP, clinical pharmacist in general oncology at the University of Washington Medicine and Fred Hutchinson Cancer Center in Seattle, WA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about antibody–drug conjugates. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 28, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the mechanism of action of antibody–drug conjugates. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 303: Cancer Symptom Management Basics: Ocular Toxicities Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction ONS Voice articles: An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities Antibody–Drug Conjugates Join the Best of Two Worlds Into One New Treatment Nursing Management of Adverse Events From Enfortumab Vedotin Therapy for Urothelial Cancer Oncology Nurses' Role in Translating Biomarker Testing Results The Pharmacist's Role in Combination Cancer Treatments ONS Voice drug reference sheets: Belantamab mafodotin-blmf Datopotamab deruxtecan-dlnk Enfortumab vedotin Fam-trastuzumab deruxtecan-nxki ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Other ONS resources: Antineoplastic Administration Huddle Card Biomarker Database Chemotherapy Huddle Card Monoclonal Antibodies Huddle Card Association of Cancer Care Centers (ACCC) antibody–drug conjugates page Drugs@FDA Hematology/Oncology Pharmacy Association (HOPA) National Cancer Institute cancer drugs page Network for Collaborative Oncology Development and Advancement (NCODA) clinical resource library ACCC/HOPA/NCODA/ONS Patient Education Sheets website To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "The mechanism of action of the chemo itself depends on what agent or what 'warhead' is attached. Generally, [ADCs] have some kind of cytotoxic mechanism related to many of the chemotherapies that we use in practice, without attachment to the antibody. Some of them can be microtubule inhibitors, vinca alkaloids like vincristine. Some of them can be topoisomerase I (TOP1) inhibitors like irinotecan. Some can be alkylating agents that cause DNA breaks. So, again, looking back at the arsenal we have of cytotoxic chemo, these can all be incorporated into the ADCs." TS 5:54 "I want to talk about a case where the biomarker is being tested, but the biomarker isn't the target that you're looking for. One good case of this is a newer agent that was approved called datopotamab deruxtecan. The datopotamab portion is specific to a target called 'trophoblast cell surface antigen 2' (TROP2), which is expressed on the surface of many epithelial cancers. This agent was first approved in hormone receptor-positive, HER2-negative breast cancer, and received accelerated approval in patients with non-small cell lung cancer (NSCLC) with an EGFR mutation. ... The antibody looks for a target, TROP2. But in both of these cases—in the breast cancer and the NSCLC—you're testing for expression of different mutations or lack thereof. You're not looking for expression of TROP2. There's more research that needs to be done about the relationship between TROP2 expression and the presence or absence of these other biomarkers, but until we know more, we're actually testing for biomarkers that aren't the target of the ADC." TS 10:22 "There are common adverse advents to antibodies and chemo in general. Because we have both of these components, we want to watch out for the adverse effects of both of them. Antibodies, as with most proteins, can trigger an immune response or an infusion reaction. So, many ADCs can also cause hypersensitivity or infusion reactions. The rates of that are really variable and depend on the actual antibodies themselves. Then you have the cytotoxic component, the chemotherapy component, which has its own characteristic side effects. So, if we think of general chemo side effects—fatigue, nausea, bone marrow suppression, alopecia—these can [occur] with a lot of ADCs as well." TS 15:34 "The rate of ocular toxicity in [mirvetuximab soravtansine] is quite high. The manufacturer reports that this can occur in up to 60% of patients. With rates so high, the manufacturer recommends a preventive strategy. For this particular agent, [they] recommend patients have required eyecare. ... This ocular toxicity is something we do see in other ADCs that don't have the same target and don't necessarily have the same payload component. For example, tisotumab vedotin and again, datopotamab deruxtecan, can both cause ocular toxicities and both would have required ocular supportive care." TS 20:08 "Overall, I feel like the future is incredibly bright for these agents. There have only been around a dozen therapies approved by the U.S. Food and Drug Administration (FDA) despite this idea—the first agent came out in 2000. So, 25 years later, there are only around a dozen FDA-approved treatments. But there are so many more that are coming through the pipeline. And as we're discovering more biomarkers and developing more specialized antibodies, it's only natural that more ADCs will follow." TS 26:50

Accreditation surveys don't start when the clipboard walks in—they start with your culture, your training, and your daily workflows. In this series finale of "Sterile Horizons," host Bobby Parker talks with Jenny Manderino, Senior Director of Accreditation Services at LifeCare Health, to break down what it really takes to stay inspection-ready in a fast-paced ASC. From culture-building tips to documentation must-dos, Jenny delivers her real-world strategies to help your team shift from reactive to ready. If you want to lead with confidence when the surveyor walks in, this episode is your blueprint for success! This engaging 5-part series dives into the realities of Ambulatory Surgery Centers (ASCs)—where tight spaces, small teams, and quick turnarounds are just part of the day-to-day. With each episode, you'll discover practical strategies to optimize your workflows, strengthen team collaboration, and deliver exceptional patient outcomes—all while navigating the fast-paced ASC environment. A special thanks to our sponsor, Solventum, for supporting this CE-approved podcast series! After finishing this interview, earn your 1 CE credit by passing the short quiz linked here: https://www.flexiquiz.com/SC/N/sterilehorizons_ep5 #BeyondClean #Solventum #SterileHorizons #ASC #Workflows #SterileProcessing #AccreditationSurvey #InspectionReady #Compliance #Survey

Let's talk about building our personal success! Today, Mardi Winder gets real about something we all deal with, and that is our habits. You know, those little routines that can either make our lives easier or trip us up, especially when we're going through big changes like a divorce.Mardi chats with Ronnie Loaiza, life coach, personal trainer, journalist, and honestly, just an all-around inspiring person. Ronnie shares her own story of how she turned her health around and discovered the power of habits in every area of life.Together, they break down simple ways to ditch old habits that don't serve you, build new ones that actually stick, and why tiny changes make the biggest difference. From self-care to money mindset, there's something here for everyone, whether you're divorced, thinking about it, or just want to create some positive changes.Mardi and Ronnie take a dive deep into why habits are so hard to change, how our brains are wired to resist anything new (even if the old ways aren't serving us), and the secret to building habits that truly stick—hint: it's all about starting small and making it realistic for your own life. They cover everything from that classic “New Year's resolution” gym rush (and why it fizzles out) to the ways scrolling on your phone or careless spending can become invisible routines that eat up time and energy.You'll definitely pick up practical tips, maybe a few laughs, and feel empowered to make your own shifts. Plus, Ronnie's got a special freebie for listeners and shares how you can reach out to her if you want more support. So grab your favorite drink, settle in, and let's get started!About the Guest:Ronnie Lo Life Coach (Ronnie Loaiza) – Habits & Celebrative Accountability. Master Certified Professional Coach with a Holistic - Mind/Body/Psyche Connection. Ronnie helps people create natural thus lasting habits – in eating, exercise, self-care, daily work, finances and productivity. Ronnie focuses on a science-backed habit-building process, with easy actions that form into habits that don't rely on tough discipline, forced motivation, or bouts of willpower! – all of which leave you with the Big-B burnout. Ronnie also works with people's 'Habitual" or Default way of thinking – You change your thought, and you change your behavior! This is true for how you behave or react to situations at work, socially, at home, and when alone. Along with coaching, Ronnie loves dancing, movies, strength-training (herself and others) and traveling. Learn more about Ronnie in 'About' at www.ronnielolifecoach.com Also see her method of tailored coaching and how you can form habits that change your life! Certified Professional Life Coach (ICF Accredited) Certified Personal Trainer with Accreditation in Corrective Exercise, Behavior Change, Senior Fitness, Women's Fitness, Mental Toughness, and Nutrition.For Ronnie's gift: PowerHabitClaritySession GiftTo connect with Ronnie :Calendar: https://calendly.com/ronnielolifecoach/zoom-or-phone-analysis Website: www.ronnielolifecoach.com LinkedIn: https://www.linkedin.com/in/ronnielolifecoach/ Substack: https://substack.com/@ronnieloaiza Instagram: https://www.instagram.com/ronnielolifecoach/About the Host: Mardi Winder is an ICF and BCC Executive and Leadership Coach, Certified Divorce Transition Coach, Certified Divorce Specialist (CDS®) and a Credentialed Distinguished Mediator in Texas. She has worked with women in executive, entrepreneur, and leadership roles, navigating personal, life, and professional transitions. She is the founder of Positive Communication Systems, LLC, and host of Real Divorce Talks, a quarterly series designed to provide education and inspiration to women at all stages of divorce. Are

"Any time the patient hears the word 'cancer,' they shut down a little bit, right? They may not hear everything that the oncologist or urologist, or whoever is talking to them about their treatment options, is saying. The oncology nurse is a great person to sit down with the patient and go over the information with them at a level they can understand a little bit more. To go over all the treatment options presented by the physician, and again, make sure that we understand their goals of care," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer treatment considerations for nurses.  Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 21, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the treatment of prostate cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 387: Prostate Cancer Screening, Early Detection, and Disparities Episode 373: Biomarker Testing in Prostate Cancer Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 208: How to Have Fertility Preservation Conversations With Your Patients Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: Communication Models Help Nurses Confidently Address Sexual Concerns in Patients With Cancer Exercise Before ADT Treatment Reduces Rate of Side Effects Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer Nurses Are Key to Patients Navigating Genitourinary Cancers Sexual Considerations for Patients With Cancer The Case of the Genomics-Guided Care for Prostate Cancer ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (Second Edition) Manual for Radiation Oncology Nursing Practice and Education (Fifth Edition) Clinical Journal of Oncology Nursing articles: Brachytherapy: Increased Use in Patients With Intermediate- and High-Risk Prostate Cancers Physical Activity: A Feasibility Study on Exercise in Men Newly Diagnosed With Prostate Cancer The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population Oncology Nursing Forum articles: An Exploratory Study of Cognitive Function and Central Adiposity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer ONS Guidelines™ for Cancer Treatment–Related Hot Flashes in Women With Breast Cancer and Men With Prostate Cancer Other ONS resources: Biomarker Database (refine by prostate cancer) Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Brachytherapy Huddle Card External Beam Radiation Huddle Card Hormone Therapy Huddle Card Luteinizing Hormone-Releasing Hormone Antagonist Huddle Card Sexuality Huddle Card American Cancer Society prostate cancer page National Comprehensive Cancer Network homepage To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "I think it's important to note that urologists are usually the ones that are doing the diagnosis of prostate cancer and really start that staging of prostate cancer. And the medical oncologists usually are not consulted until the patient is at a greater stage of prostate cancer. I find that it's important to state because a lot of our patients start with urologists, and by the time they've come to us, they're a lot further staged. But once a prostate cancer has been suspected, the patient needs to be staged for the extent of disease prior to that physician making any treatment recommendations. The staging includes doing a core biopsy of the prostate gland. During this core biopsy, they take multiple different cores at different areas throughout the prostate to really look to see what the cancer looks like." TS 1:46 "[For] the very low- and low-risk group, the most common [treatment] is active surveillance. ... Patients can be offered other options such as radiation therapy or surgery if they're not happy with active surveillance. ... The intermediate-risk group has favorable and unfavorable [status]. So, if they're a favorable, their Gleason score is usually a bit lower, things are not as advanced. These patients are offered active surveillance and then either radical prostatectomy with possible removal of lymph nodes or radiation—external beam or brachytherapy. If a patient has unfavorable intermediate risk, they are offered radical prostatectomy with removal of lymph nodes, external radiation therapy plus hormone therapy, or external radiation with brachytherapy. All three of these are offered to patients, although most frequently we see that our patients are taken in for radical prostatectomy. For the high- or very high-risk [group], patients are offered radiation therapy with hormone therapy, typically for one to three years. And then radical prostatectomy with removal of lymph nodes could also be offered for those patients." TS 7:55 "Radiation can play a role in any risk group depending on the patient's preference. ... The types of radiation that we use are external beam, brachytherapy, which is an internal therapy, and radiopharmaceuticals, [which are] more for advanced cancer, but we are seeing them used in prostate [cancer] as well. External beam radiation focuses on the tumor and any metastasis we may have with the tumor. It can be used in any risk [group] and for recurrence if radiation has not been done previously. If a patient has already been radiated to the pelvic area or to the prostate, radiation is usually not given again because we don't want to damage the patient any further. Brachytherapy is when we put radioactive pellets directly into the prostate. For early-stage prostate cancer, this can be given alone. And for patients who have a higher risk of the cancer growing outside the prostate, it can be given in combination with external beam radiation. It's important to note with brachytherapy, it cannot be used on patients who've had a transurethral resection of the prostate or any urinary problems. And if the patient has a large prostate, they may have to be on some hormone therapy prior to brachytherapy, just to shrink that prostate down a little bit to get the best effect. ... Radiopharmaceuticals treat the prostate-specific membrane antigen." TS 11:05 "The side effects of surgery are usually what deter the patient from wanting surgery. The first one is urinary incontinence. A lot of times, a patient has a lot of urinary incontinence after they have surgery. The other one is erectile dysfunction. A lot of patients may not want to have erectile dysfunction. Or, if having an erection is important to the patient, they may not want to have surgery to damage that. In this day and age, physicians have gotten a lot better at doing nerve-sparing surgeries. And so they really do try to do that so that the patient does not have any issues with erectile dysfunction after surgery. But [depending on] the extent of the cancer where it's growing around those nerves or there are other things going on, they may not be able to save those nerves." TS 15:26 "Luteinizing hormone-releasing hormone, or LHRH antagonists or analogs, lower the amount of testosterone made by the testicles. We're trying to stop those hormones from growing to prevent the cancer. ... When we lower the testosterone very quickly, there can be a lot more side effects. But if we lower it a little bit less, we can maybe help prevent some of them. The side effects are important. When I was writing this up, I was thinking, 'Okay, this is basically what women go through when they go through menopause.' We're decreasing the estrogen. We're now decreasing the testosterone. So, the patients can have reduced or absent sexual desire, they can have gynecomastia, hot flashes, osteopenia, anemia, decreased mental sharpness, loss of muscle mass, weight gain, and fatigue." TS 17:50 "What we all need to remember is that no patient is the same. They may not have the same goals for treatment as the physicians or the nurses want for the patient. We talked about surgery as the most common treatment modality that's presented to patients, but it's not necessarily the option that they want. It's really important for healthcare professionals to understand their biases before talking to the patients and the family. It's also important to remember that not all patients are in heterosexual relationships, so we need to explain recovery after treatment to meet the needs of our patients and their sexual relationships, which is sometimes hard for us. But remembering that—especially gay men—they may not have the same recovery period as a heterosexual male when it comes to sexual relationships. So, making sure that we have those frank conversations with our patients and really check our biases prior to going in and talking with them." TS 27:16

This episode—recorded live at Becker's 31st Annual The Business and Operations of ASCs event—features Dr. Ken Grubbs, Executive Vice President, Accreditation and Certification Operations, and Chief Nursing Officer, Joint Commission. He discusses how Accreditation 360 is shaping the future of healthcare quality, reducing administrative burden, and promoting collaboration to improve patient outcomes. This episode is sponsored by Joint Commission.